[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1057
1. Zhao J, Iida A, Ouchi Y, Satoh S, Watanabe S: M6a is expressed in the murine neural retina and regulates neurite extension. Mol Vis; 2008;14:1623-30
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] M6a is expressed in the murine neural retina and regulates neurite extension.
  • PURPOSE: Glycoprotein m6a (M6a) is a cell-surface glycoprotein that belongs to the myelin proteolipid protein family.
  • M6a is expressed mainly in the nervous system, and its expression and function in mammalian retina have not been described.
  • Using proteomics analysis of mouse retinal membrane fractions, we identified M6a as a retinal membrane protein that is strongly expressed at embryonic stages.
  • Our aim was to reveal the function of M6a in development of mouse retina in this work.
  • METHODS: Detailed expression pattern of M6a was examined by immunostaining using frozen sections of mouse retina obtained at various developmental stages.
  • For functional analysis of M6a in mouse retinal development, we performed retorovirus-mediated overexpression of M6a in mouse retinal explant culture.
  • RESULTS: M6a transcripts were strongly expressed in embryonic retina.
  • After completion of retinal differentiation, the level of expression decreased as mouse development progressed.
  • Immunohistochemistry showed that in the immature mouse retina, M6a was strongly expressed in the axons of retinal ganglion cells.
  • After birth, M6a expression was confined to the inner plexiform layer, and finally, to the inner and outer plexiform layers of adult mouse retina.
  • M6a expression was completely paralleled by that of the synaptic marker, synaptophysin.
  • Mouse retinal progenitor cells that overexpressed M6a following retrovirus-mediated gene transfer were subjected to in vitro explant or monolayer cultures.
  • The neurite outgrowth of M6a-overexpressing retinal cells was strikingly enhanced, although M6a did not affect differentiation and proliferation.
  • CONCLUSIONS: These results suggest that M6a plays a role in retinal development by regulating neurites, and it may also function to modulate synaptic activities in the adult retina.
  • [MeSH-minor] Animals. Biomarkers / metabolism. Cell Differentiation. Cell Lineage. Cell Proliferation. Gene Expression Regulation, Developmental. Mice. Mice, Inbred ICR. Mitosis. Protein Transport. Stem Cells / cytology. Stem Cells / metabolism. Synapses / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2007 Jan 1;301(1):141-54 [17069792.001]
  • [Cites] Dev Biol. 2006 Apr 1;292(1):265-76 [16499901.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):93-8 [10638760.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1063-6 [10871756.001]
  • [Cites] Trends Neurosci. 2002 Jan;25(1):32-8 [11801336.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7398-407 [12196561.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):722-8 [12359212.001]
  • [Cites] Brain Res Dev Brain Res. 2003 Oct 10;145(1):93-105 [14519497.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4513-21 [15121868.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] J Neurosci. 1991 Jun;11(6):1617-26 [1904480.001]
  • [Cites] J Neurobiol. 1992 Feb;23(1):71-88 [1564456.001]
  • [Cites] Dev Dyn. 1992 Aug;194(4):311-25 [1286213.001]
  • [Cites] Neuron. 1993 Sep;11(3):423-31 [8398137.001]
  • [Cites] Neuron. 1994 Mar;12(3):583-95 [7512350.001]
  • [Cites] J Comp Neurol. 1996 Jul 8;370(4):465-78 [8807448.001]
  • [Cites] Mech Dev. 1998 Aug;76(1-2):3-18 [9767078.001]
  • [Cites] J Neurosci Res. 1999 Jul 1;57(1):13-22 [10397631.001]
  • [Cites] J Neurocytol. 1998 Sep;27(9):695-703 [10447243.001]
  • [Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4473-83 [16179606.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17196-201 [16286650.001]
  • [Cites] Biochem J. 2007 Nov 15;408(1):51-9 [17688421.001]
  • (PMID = 18776950.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Gpm6a protein, mouse; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ PMC2529470
  •  go-up   go-down


2. Liang YJ, Wu DF, Stumm R, Höllt V, Koch T: Membrane glycoprotein M6A promotes mu-opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway. Cell Res; 2008 Jul;18(7):768-79
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane glycoprotein M6A promotes mu-opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway.
  • The interaction of mu-opioid receptor (MOPr) with the neuronal membrane glycoprotein M6a is known to facilitate MOPr endocytosis in human embryonic kidney 293 (HEK293) cells.
  • To further study the role of M6a in the post-endocytotic sorting of MOPr, we investigated the agonist-induced co-internalization of MOPr and M6a and protein targeting after internalization in HEK293 cells that co-expressed HA-tagged MOPr and Myc-tagged M6a.
  • We found that M6a, MOPr, and Rab 11, a marker for recycling endosomes, co-localized in endocytotic vesicles, indicating that MOPr and M6a are primarily targeted to recycling endosomes after endocytosis.
  • Furthermore, co-expression of M6a augmented the post-endocytotic sorting of delta-opioid receptors into the recycling pathway, indicating that M6a might have a more general role in opioid receptor post-endocytotic sorting.
  • The enhanced post-endocytotic sorting of MOPr into the recycling pathway was accompanied by a decrease in agonist-induced receptor down-regulation of M6a in co-expressing cells.
  • We tested the physiological relevance of these findings in primary cultures of cortical neurons and found that co-expression of M6a markedly increased the translocation of MOPrs from the plasma membrane to intracellular vesicles at steady state and significantly enhanced both constitutive and agonist-induced receptor endocytosis.
  • In conclusion, our results strongly indicate that M6a modulates MOPr endocytosis and post-endocytotic sorting and has an important role in receptor regulation.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574501.001).
  • [ISSN] 1748-7838
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / OPRM1 protein, human; 0 / Receptors, Opioid, mu; EC 2.1.1.- / Methyltransferases; EC 2.1.1.62 / METTL3 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins; EC 3.6.1.- / rab11 protein
  •  go-up   go-down


3. Sakuragi Y, Kolter R: Quorum-sensing regulation of the biofilm matrix genes (pel) of Pseudomonas aeruginosa. J Bacteriol; 2007 Jul;189(14):5383-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quorum-sensing regulation of the biofilm matrix genes (pel) of Pseudomonas aeruginosa.
  • Although QS regulation of swarming and DNA release has been shown to play important roles in biofilm development, regulation of genes directly involved in biosynthesis of biofilm matrix has not been described.
  • Here, transcription of the pel operon, essential for the production of a glucose-rich matrix exopolysaccharide, is shown to be greatly reduced in lasI and rhlI mutants.
  • Chemical complementation of the lasI mutant with 3-oxo-dodecanoyl homoserine lactone restores pel transcription to the wild-type level and biofilm formation ability.
  • These findings thus connect QS signaling and transcription of genes responsible for biofilm matrix biosynthesis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biotechniques. 2000 Nov;29(5):948-50, 952 [11084852.001]
  • [Cites] Mol Microbiol. 2006 Dec;62(5):1264-77 [17059568.001]
  • [Cites] J Bacteriol. 2001 Nov;183(22):6676-83 [11673439.001]
  • [Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]
  • [Cites] J Bacteriol. 2004 May;186(10):2936-45 [15126453.001]
  • [Cites] Annu Rev Microbiol. 1987;41:435-64 [3318676.001]
  • [Cites] Science. 1998 Apr 10;280(5361):295-8 [9535661.001]
  • [Cites] Mol Microbiol. 1998 Sep;29(6):1321-30 [9781871.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):745-54 [15525535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15833-9 [15505212.001]
  • [Cites] Trends Microbiol. 2005 Jan;13(1):20-6 [15639628.001]
  • [Cites] Trends Microbiol. 2005 Jan;13(1):27-33 [15639629.001]
  • [Cites] Microbiology. 2005 Mar;151(Pt 3):985-97 [15758243.001]
  • [Cites] Environ Microbiol. 2005 Apr;7(4):459-71 [15816912.001]
  • [Cites] RNA. 2005 Oct;11(10):1579-87 [16131593.001]
  • [Cites] Mol Microbiol. 2006 Feb;59(4):1114-28 [16430688.001]
  • [Cites] FEMS Microbiol Rev. 2006 Mar;30(2):274-91 [16472307.001]
  • [Cites] Int J Med Microbiol. 2006 Apr;296(2-3):73-81 [16476569.001]
  • [Cites] Cell Microbiol. 2006 Dec;8(12):1841-9 [17026480.001]
  • [Cites] J Bacteriol. 2001 Oct;183(19):5529-34 [11544214.001]
  • (PMID = 17496081.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM058213; United States / NIGMS NIH HHS / GM / GM58213
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins
  • [Other-IDs] NLM/ PMC1951888
  •  go-up   go-down


Advertisement
4. Chung IY, Choi KB, Heo YJ, Cho YH: Effect of PEL exopolysaccharide on the wspF mutant phenotypes in Pseudomonas aeruginosa PA14. J Microbiol Biotechnol; 2008 Jul;18(7):1227-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of PEL exopolysaccharide on the wspF mutant phenotypes in Pseudomonas aeruginosa PA14.
  • Here, we characterized the role of cyclic diguanylate (c-di-GMP) and EPS (PEL) overproduction in the wspF mutant phenotypes of P. aeruginosa PA14 (wrinkly appearance, hyperadherence, impaired motilities, and reduced virulence in acute infections).
  • We confirmed that the elevated c-di-GMP level plays a key role in all the wspF mutant phenotypes listed above, as assessed by ectopic expression of a c-di-GMP-degrading phophodiesterase (PvrR) in the wspF mutant.
  • In contrast, PEL EPS, which is overproduced in the wspF mutant, was necessary for wrinkly appearance and hyperadherence, but not for the impaired flagellar motilities and the attenuated virulence of the wspF mutant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667850.001).
  • [ISSN] 1017-7825
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Polysaccharides, Bacterial; 61093-23-0 / bis(3',5')-cyclic diguanylic acid; EC 3.1.- / Esterases; H2D2X058MU / Cyclic GMP
  •  go-up   go-down


5. Sharma P, Dhingra KK, Roy S, Singh T: An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia. J Pediatr Hematol Oncol; 2009 Mar;31(3):220-1
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.
  • The case of a 12 yr old female with bcr-abl positive chronic myeloid leukemia who subsequently developed a fatal AML-M6b (pure erythroleukemia) blast crisis is presented.
  • The case is unique for its rarity of occurrence and for the striking resemblance that the circulating proerythroblasts showed to the giant cells characteristically seen in Parvovirus B19-induced acute pure red cell aplasia.
  • This is, to the best of our knowledge, the first description of such cells in a blast crisis of chronic myeloid leukemia.
  • [MeSH-major] Blast Crisis / pathology. Erythroblasts / pathology. Leukemia, Erythroblastic, Acute / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262253.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


6. Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD, Henry D, Harrington WJ Jr, Damania BA, Dittmer DP: Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood; 2007 Mar 1;109(5):2165-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.
  • Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma-associated herpesvirus (KSHV).
  • We find that (1) rapamycin is efficacious against PEL in culture and in a murine xenograft model;.
  • (2) mTOR, its activator Akt, and its target p70S6 kinase are phosphorylated in PEL;.
  • This validates sirolimus as a new treatment option for PEL.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1393-400 [10555008.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] J Infect Dis. 2000 Dec;182(6):1809-10 [11069261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):136-41 [11134523.001]
  • [Cites] Clin Infect Dis. 2001 May 15;32(10):1502-5 [11317254.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1758-64 [11410517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5 [11504907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] J Infect. 2001 Oct;43(3):195-9 [11798259.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13907-17 [11847216.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7291-7 [12499272.001]
  • [Cites] J Virol. 2003 May;77(10):5759-73 [12719569.001]
  • [Cites] Nat Med. 2003 May;9(5):554-61 [12692543.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4472-80 [12907620.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):343-8 [14667501.001]
  • [Cites] J Virol. 2004 Feb;78(4):1918-27 [14747556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6 [15047889.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Nat Rev Microbiol. 2004 Aug;2(8):656-68 [15263900.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] Cancer Res. 1988 Feb 1;48(3):589-601 [3335022.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2475-81 [9516148.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1358-63 [9801396.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]
  • [Cites] Transplantation. 1999 Apr 27;67(8):1200-1 [10232577.001]
  • [Cites] Transplantation. 1999 May 15;67(9):1236-42 [10342315.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Virol. 1999 Jul;73(7):6136-40 [10364372.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1122-8 [15467718.001]
  • [Cites] Trends Biochem Sci. 2005 Jan;30(1):35-42 [15653324.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3102-8 [15837766.001]
  • [Cites] AIDS Rev. 2005 Jan-Mar;7(1):56-61 [15875661.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):179-83 [16169463.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):168-74 [16397229.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3658-66 [16585191.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):683-5 [15220917.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Eur Cytokine Netw. 1999 Dec;10(4):501-8 [10586116.001]
  • (PMID = 17082322.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL083469; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA096500; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIAID NIH HHS / AI / AI057157; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA098110; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA112935; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA098110; United States / NHLBI NIH HHS / HL / R01 HL083469; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NIAID NIH HHS / AI / U54 AI057157; United States / NCI NIH HHS / CA / R01 CA096500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1801055
  •  go-up   go-down


7. van Gijn J, Gijselhart J: [Professor Pel and 'glandular fever']. Ned Tijdschr Geneeskd; 2009;153:A1215
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Professor Pel and 'glandular fever'].
  • [Transliterated title] Professor Pel en 'klierkoorts'.
  • Pieter Klaesz Pel (1852-1919) was professor of internal medicine at the University of Amsterdam, for more than 35 years.
  • It is contested whether the patients in question had Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20051175.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Biography; English Abstract; Historical Article; Journal Article; Portraits
  • [Publication-country] Netherlands
  • [Personal-name-as-subject] Pel PK
  •  go-up   go-down


8. Wu DF, Koch T, Liang YJ, Stumm R, Schulz S, Schröder H, Höllt V: Membrane glycoprotein M6a interacts with the micro-opioid receptor and facilitates receptor endocytosis and recycling. J Biol Chem; 2007 Jul 27;282(30):22239-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane glycoprotein M6a interacts with the micro-opioid receptor and facilitates receptor endocytosis and recycling.
  • Using a yeast two-hybrid screen, the neuronal membrane glycoprotein M6a, a member of the proteolipid protein family, was identified to be associated with the mu-opioid receptor (MOPr).
  • Bioluminescence resonance energy transfer and co-immunoprecipitation experiments confirmed that M6a interacts agonist-independently with MOPr in human embryonic kidney 293 cells co-expressing MOPr and M6a.
  • Co-expression of MOPr with M6a, but not with M6b or DM20, exists in many brain regions, further supporting a specific interaction between MOPr and M6a.
  • After opioid treatment M6a co-internalizes and then co-recycles with MOPr to cell surface in transfected human embryonic kidney 293 cells.
  • Moreover, the interaction of M6a and MOPr augments constitutive and agonist-dependent internalization as well as the recycling rate of mu-opioid receptors.
  • On the other hand, overexpression of a M6a-negative mutant prevents mu-opioid receptor endocytosis, demonstrating an essential role of M6a in receptor internalization.
  • In addition, we demonstrated the interaction of M6a with a number of other G protein-coupled receptors (GPCRs) such as the delta-opioid receptor, cannabinoid receptor CB1, and somatostatin receptor sst2A, suggesting that M6a might play a general role in the regulation of certain GPCRs.
  • Taken together, these data provide evidence that M6a may act as a scaffolding molecule in the regulation of GPCR endocytosis and intracellular trafficking.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548356.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Opioid, mu; 0 / Recombinant Proteins
  •  go-up   go-down


9. Matsumoto T, Matsubara M, Oana K, Kasuga E, Suzuki T, Hidaka E, Shigemura T, Yamauchi K, Honda T, Ota H, Kawakami Y: First case of bacteremia due to chromosome-encoded CfxA3-beta-lactamase-producing Capnocytophaga sputigena in a pediatric patient with acute erythroblastic leukemia. Eur J Med Res; 2008 Mar 31;13(3):133-5
Genetic Alliance. consumer health - Acute Erythroblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First case of bacteremia due to chromosome-encoded CfxA3-beta-lactamase-producing Capnocytophaga sputigena in a pediatric patient with acute erythroblastic leukemia.
  • Bacteremia due to Capnocytophaga sputigena occurred in a 4-year and 9-month-old Japanese girl patient with acute erythroblastic leukemia in Shinshu University Hospital, Japan.
  • The causative Capnocytophaga sputigena isolate was found to be a beta-lactamase-producer demonstrating to possess cfxA3 gene.
  • The gene responsible for the production of CfxA3-beta-lactamase was proved to be chromosome-encoded, by means of southern hybridization analysis.
  • [MeSH-major] Bacteremia / microbiology. Capnocytophaga / isolation & purification. Chromosomes, Bacterial. Leukemia, Erythroblastic, Acute / complications. beta-Lactamases / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499560.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; EC 3.5.2.6 / beta-Lactamases
  •  go-up   go-down


10. Brocco MA, Fernández ME, Frasch AC: Filopodial protrusions induced by glycoprotein M6a exhibit high motility and aids synapse formation. Eur J Neurosci; 2010 Jan;31(2):195-202

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Filopodial protrusions induced by glycoprotein M6a exhibit high motility and aids synapse formation.
  • M6a is a neuronal membrane glycoprotein whose expression diminishes during chronic stress.
  • M6a overexpression in rat primary hippocampal neurons induces the formation of filopodial protrusions that could be spine precursors.
  • As the filopodium and spine motility has been associated with synaptogenesis, we analysed the motility of M6a-induced protrusions by time-lapse imaging.
  • Our data demonstrate that the motile protrusions formed by the neurons overexpressing M6a were more abundant and moved faster than those formed in control cells.
  • When different putative M6a phosphorylation sites were mutated, the neurons transfected with a mutant lacking intracellular phosphorylation sites bore filopodia, but these protrusions did not move as fast as those formed by cells overexpressing wild-type M6a.
  • This suggests a role for M6a phosphorylation state in filopodium motility.
  • Furthermore, we show that M6a-induced protrusions could be stabilized upon contact with presynaptic region.
  • The behavior of filopodia from M6a-overexpressing cells and control cells was alike.
  • Thus, M6a-induced protrusions may be spine precursors that move to reach presynaptic membrane.
  • We suggest that M6a is a key molecule for spine formation during development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20074218.001).
  • [ISSN] 1460-9568
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


11. Honda Y, Manabe A, Tsuchida M, Zaike Y, Masunaga A, Inoue M, Kobayashi R, Ohtsuka Y, Kikuchi A, Nakahata T, MDS Committee, the Japanese Society of Pediatric Hematology: Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children. Int J Hematol; 2008 Dec;88(5):524-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children.
  • The distinction between RAEB, RAEB-T and AML M6a is difficult when erythroblasts in the bone marrow (BM) exceed 50%.
  • We analyzed 19 children (2 RAEB, 13 RAEB-T and 4 AML M6a) enrolled in a prospective pathological central review in Japan and divided them into two groups according to the myeloblasts percentage among non-erythroid cells in BM: group A (n = 8), 5-19% myeloblasts; group B (n = 11), 20% or more myeloblasts.
  • Six with group A and seven with group B treated with AML type chemotherapy achieved complete remission.
  • Five with group A and seven with group B undergoing SCT are alive at a median of 3 years after diagnosis.
  • Erythroblast-rich RAEB and AML M6a in children have similar characteristics and may belong to a single disease entity.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / pathology. Erythroblasts / pathology. Granulocyte Precursor Cells / pathology. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Japan. Leukocyte Count. Male. Prospective Studies. Remission Induction. Stem Cell Transplantation. Time Factors. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Int. 2005 Oct;47(5):572-4 [16190967.001]
  • [Cites] Blood. 2006 Jul 15;108(2):419-25 [16609072.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1713-20 [11681412.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):758-67 [12780790.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1714-20 [11535502.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):17-22 [16856158.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):33-9 [11918530.001]
  • [Cites] Leukemia. 2003 Feb;17(2):277-82 [12592323.001]
  • [Cites] Leuk Res. 2003 May;27(5):397-404 [12620291.001]
  • [Cites] Semin Hematol. 1996 Apr;33(2):111-26 [8722682.001]
  • [Cites] Br J Haematol. 1982 Jun;51(2):189-99 [6952920.001]
  • [Cites] Am J Clin Pathol. 2005 Aug;124(2):191-8 [16040288.001]
  • [Cites] Leuk Res. 2002 May;26(5):423-9 [11916513.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1399-401 [12145675.001]
  • (PMID = 18951200.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


12. Knoblauch RE, Thompson CB: Targeting tumor metabolism: biguanides as anti-neoplastic agents. J Clin Oncol; 2009 May 20;27(15_suppl):e14592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14592 Background: During the process of malignant transformation, the tumor cell adopts a new form of metabolism, characterized by aerobic glycolysis and altered TCA cycle flux, that enable it to meet the energetic and biosynthetic demands of proliferation.
  • METHODS: We have characterized the proliferative and metabolic effects of phenformin, a member of the biguanide family of compounds used in the treatment of diabetes, on the bcr-abl expressing K562 erythroleukemia cell line, and compared the resulting phenotype to those of imatinib and rapamycin, two targeted agents used in the treatment of malignant disease.
  • Phenformin treatment eliminated the mitochondrial contribution to anabolic metabolism, through inhibition of Complex I of the Electron Transport Chain, as demonstrated by reduced oxygen consumption and intracellular ATP levels.
  • CONCLUSIONS: Our results confirm the importance of metabolism to the proliferation of malignant cells, thereby validating anabolic metabolism's potential for therapeutic intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963742.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Speake G, Klinowska T, Hickinson M, Marshall G, Smith P, Vincent J, Anderton J, Gray N, Smith I, Ogilvie D: Characterization of AZD8931, a potent reversible small molecule inhibitor against epidermal growth factor receptor (EGFR), erythroblastic leukemia viral oncogene homolog 2 (HER2) and 3 (HER3) with a unique and balanced pharmacological profile. J Clin Oncol; 2009 May 20;27(15_suppl):11072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of AZD8931, a potent reversible small molecule inhibitor against epidermal growth factor receptor (EGFR), erythroblastic leukemia viral oncogene homolog 2 (HER2) and 3 (HER3) with a unique and balanced pharmacological profile.
  • Characterization of a novel tyrosine kinase inhibitor with a potent and balanced profile against EGFR, HER2 (erbB2), and HER3 (erbB3) has been carried out.
  • These assays have provided unique insights into the pharmacology of these drugs that result from the varying levels of HER and their associated ligands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Arumugam PI, Scholes J, Perelman N, Xia P, Yee JK, Malik P: Improved Human β-globin Expression from Self-inactivating Lentiviral Vectors Carrying the Chicken Hypersensitive Site-4 (cHS4) Insulator Element. Mol Ther; 2007 Oct;15(10):1863-1871

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Effective gene therapy for β-thalassemia major (β-TM) requires consistent, high expression of human β-globin (hβ-globin) in red blood cells (RBCs).
  • Several groups have now shown that lentiviral (LV) vectors stably transmit the hβ/hγ-globin genes and large elements of the locus control region, resulting in correction of the murine thalassemia intermedia (TI) phenotype and survival of mice with the TM phenotype.
  • We observed a consistent twofold-higher hβ expression from insulated vectors in single-copy mouse erythroleukemia cell clones, an increase that resulted from reduced position effect variegation (PEV) and increased probability of expression from individual integrants.
  • These studies have important implications for vector design for clinical trials for gene therapy for hemoglobinopathies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182916.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Vasseur P, Vallet-Gely I, Soscia C, Genin S, Filloux A: The pel genes of the Pseudomonas aeruginosa PAK strain are involved at early and late stages of biofilm formation. Microbiology; 2005 Mar;151(Pt 3):985-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pel genes of the Pseudomonas aeruginosa PAK strain are involved at early and late stages of biofilm formation.
  • Biofilm-deficient P. aeruginosa PAK strains affected in a seven-gene cluster called pel were characterized.
  • The pel genes encode proteins with similarity to components involved in polysaccharide biogenesis, of which PelF is a putative glycosyltransferase.
  • The pel genes were previously identified in the P. aeruginosa PA14 strain as required for the production of a glucose-rich matrix material involved in the formation of a thick pellicle and resistant biofilm.
  • However, in PA14, the pel mutants have no clear phenotype in the initiation phase of attachment.
  • It was shown that pel mutations in the PAK strain had little influence on biofilm initiation but, as in PA14, appeared to generate the least robust and mature biofilms.
  • Strikingly, by constructing pel mutants in a non-piliated P. aeruginosa PAK strain, an unexpected effect of the pel mutation in the early phase of biofilm formation was discovered, since it was observed that these mutants were severely defective in the attachment process on solid surfaces.
  • The pel gene cluster is conserved in other Gram-negative bacteria, and mutation in a Ralstonia solanacearum pelG homologue, ragG, led to an adherence defect.
  • [MeSH-minor] Bacterial Adhesion. Culture Media. DNA Transposable Elements. Gene Expression Regulation, Bacterial. Glycosyltransferases / genetics. Glycosyltransferases / metabolism. Hydrophobic and Hydrophilic Interactions. Multigene Family. Mutation. Polysaccharides, Bacterial / genetics. Polysaccharides, Bacterial / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15758243.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Culture Media; 0 / DNA Transposable Elements; 0 / Polysaccharides, Bacterial; EC 2.4.- / Glycosyltransferases
  •  go-up   go-down


16. Cooper B, Werner HB, Flügge G: Glycoprotein M6a is present in glutamatergic axons in adult rat forebrain and cerebellum. Brain Res; 2008 Mar 4;1197:1-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycoprotein M6a is present in glutamatergic axons in adult rat forebrain and cerebellum.
  • Glycoprotein M6a is a neuronally expressed member of the proteolipid protein (PLP) family of tetraspans.
  • In vitro studies suggested a potential role in neurite outgrowth and spine formation and previous investigations have identified M6a as a stress-regulated gene.
  • To investigate whether the distribution of M6a correlates with neuronal structures susceptible to alterations in response to stress, we localized M6a expression in neurons of hippocampal formation, prefrontal cortex and cerebellum using in situ hybridization and confocal immunofluorescence microscopy.
  • In situ hybridization confirmed that M6a is expressed in dentate gyrus and cerebellar granule neurons and in hippocampal and cortical pyramidal neurons.
  • Confocal microscopy localized M6a immunoreactivity to distinct sites within axonal membranes, but not in dendrites or neuronal somata.
  • Moreover, M6a colocalized with synaptic markers of glutamatergic, but not GABAergic nerve terminals.
  • M6a expression in the adult brain is particularly strong in unmyelinated axonal fibers, i.e. cerebellar parallel and hippocampal mossy fibers.
  • In contrast, myelinated axons exhibit only minimal M6a immunoreactivity localized exclusively to terminal regions.
  • The present neuroanatomical data demonstrate that M6a is an axonal component of glutamatergic neurons and that it is localized to distinct sites of the axonal plasma membrane of pyramidal and granule cells.
  • [MeSH-minor] Animals. Fluorescent Antibody Technique. Gene Expression. Glutamine. In Situ Hybridization. Male. Microscopy, Confocal. RNA, Messenger / analysis. Rats. Rats, Sprague-Dawley. Vesicular Glutamate Transport Proteins / metabolism

  • Hazardous Substances Data Bank. Glutamine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241840.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Vesicular Glutamate Transport Proteins; 0RH81L854J / Glutamine
  •  go-up   go-down


17. Fuchsova B, Fernández ME, Alfonso J, Frasch AC: Cysteine residues in the large extracellular loop (EC2) are essential for the function of the stress-regulated glycoprotein M6a. J Biol Chem; 2009 Nov 13;284(46):32075-88
Hazardous Substances Data Bank. CYSTEINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cysteine residues in the large extracellular loop (EC2) are essential for the function of the stress-regulated glycoprotein M6a.
  • Gpm6a was identified as a stress-responsive gene in the hippocampal formation.
  • This gene is down-regulated in the hippocampus of both socially and physically stressed animals, and this effect can be reversed by antidepressant treatment.
  • Previously we showed that the stress-regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation.
  • In the present work, mutational analysis was used to characterize the action of M6a at the molecular level.
  • The presence of cysteines 162 and 202 is essential for the efficient cell surface expression of the M6a protein.
  • In contrast, cysteines 174 and 192, which form a disulfide bridge as shown by biochemical analysis, are not required for the efficient surface expression of M6a.
  • Their mutation to alanine does not interfere with the localization of M6a to filopodial protrusions in primary hippocampal neurons.
  • In non-permeabilized cells, these mutant proteins are not recognized by a function-blocking monoclonal antibody directed to M6a.
  • Taken together, this study demonstrates that cysteines in the EC2 domain are critical for the role of M6a in filopodium outgrowth and synaptogenesis.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2000 Nov 1;351 Pt 3:629-37 [11042117.001]
  • [Cites] Neuroscience. 2000;97(2):253-66 [10799757.001]
  • [Cites] EMBO J. 2001 Jan 15;20(1-2):12-8 [11226150.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4853-62 [11087758.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25005-13 [11325968.001]
  • [Cites] Virus Res. 2001 Nov 28;80(1-2):1-10 [11597743.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):40055-64 [11483611.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40545-54 [11504738.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 23):4143-51 [11739647.001]
  • [Cites] Mol Cell Neurosci. 2001 Dec;18(6):593-605 [11749036.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7398-407 [12196561.001]
  • [Cites] J Cell Biol. 2002 Sep 30;158(7):1299-309 [12356873.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):722-8 [12359212.001]
  • [Cites] Science. 2002 Oct 25;298(5594):770-6 [12399577.001]
  • [Cites] Trends Biochem Sci. 2003 Feb;28(2):106-12 [12575999.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(11):2447-56 [12814376.001]
  • [Cites] Trends Immunol. 2003 Nov;24(11):610-7 [14596886.001]
  • [Cites] J Neurosci Res. 2003 Dec 1;74(5):744-53 [14635225.001]
  • [Cites] Biochem J. 2004 Jan 15;377(Pt 2):407-17 [14556650.001]
  • [Cites] Eur J Neurosci. 2004 Feb;19(3):659-66 [14984416.001]
  • [Cites] J Neurosci. 1991 Jun;11(6):1617-26 [1904480.001]
  • [Cites] J Neurobiol. 1992 Feb;23(1):71-88 [1564456.001]
  • [Cites] Biochemistry. 1992 Dec 15;31(49):12289-96 [1281423.001]
  • [Cites] Neuron. 1993 Sep;11(3):423-31 [8398137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4029-33 [8171030.001]
  • [Cites] EMBO J. 1994 May 15;13(10):2322-30 [8194524.001]
  • [Cites] Neuroscience. 1995 Nov;69(1):83-8 [8637635.001]
  • [Cites] Neuroscience. 1995 Nov;69(1):89-98 [8637636.001]
  • [Cites] J Comp Neurol. 1996 Jul 8;370(4):465-78 [8807448.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14002-8 [9391142.001]
  • [Cites] Acta Anat (Basel). 1998;162(2-3):75-84 [9831753.001]
  • [Cites] Biochem J. 1999 May 15;340 ( Pt 1):103-11 [10229664.001]
  • [Cites] J Neurocytol. 1998 Sep;27(9):695-703 [10447243.001]
  • [Cites] Nat Rev Immunol. 2005 Feb;5(2):136-48 [15688041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1939-44 [15677332.001]
  • [Cites] Physiology (Bethesda). 2005 Aug;20:218-24 [16024509.001]
  • [Cites] BMC Struct Biol. 2005;5:11 [15985154.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17196-201 [16286650.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11 [16314869.001]
  • [Cites] Biol Psychiatry. 2006 Feb 1;59(3):244-51 [16140276.001]
  • [Cites] Neuroscience. 2006 Jun 30;140(2):597-606 [16600515.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(20):7707-18 [16908530.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):22239-47 [17548356.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1855-67 [17644758.001]
  • [Cites] Brain Res. 2008 Mar 4;1197:1-12 [18241840.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):707-11 [18163405.001]
  • [Cites] Mol Vis. 2008;14:1623-30 [18776950.001]
  • [Cites] Stem Cells Dev. 2008 Aug;17(4):641-51 [18522499.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):167-70 [10655063.001]
  • [Cites] J Virol. 2000 Apr;74(8):3642-9 [10729140.001]
  • [Cites] Int J Dev Biol. 2000;44(6):725-31 [11061437.001]
  • (PMID = 19737934.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; K848JZ4886 / Cysteine
  • [Other-IDs] NLM/ PMC2797278
  •  go-up   go-down


18. Cooper B, Fuchs E, Flügge G: Expression of the axonal membrane glycoprotein M6a is regulated by chronic stress. PLoS One; 2009;4(1):e3659

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the axonal membrane glycoprotein M6a is regulated by chronic stress.
  • The present study shows that chronic stress also regulates expression of M6a, a glycoprotein which is localised in axonal membranes.
  • We have previously demonstrated that M6a is a component of glutamatergic axons.
  • The present data reveal that it is the splice variant M6a-Ib, not M6a-Ia, which is strongly expressed in the brain.
  • Chronic stress in male rats (3 weeks daily restraint) has regional effects: quantitative in situ hybridization demonstrated that M6a-Ib mRNA in dentate gyrus granule neurons and in CA3 pyramidal neurons is downregulated, whereas M6a-Ib mRNA in the medial prefrontal cortex is upregulated by chronic stress.
  • Enhanced M6a-Ib expression in the medial prefrontal cortex (in areas prelimbic and infralimbic cortex) might be interpreted as a compensatory mechanism in response to changes in axonal projections from the hippocampus.
  • [MeSH-major] Axons / metabolism. Brain / metabolism. Gene Expression Regulation. Membrane Glycoproteins / genetics. Nerve Tissue Proteins / genetics. Stress, Physiological / physiology
  • [MeSH-minor] Animals. Down-Regulation. Gene Expression. In Situ Hybridization. Kidney / metabolism. Male. Neurons / metabolism. Protein Isoforms. RNA, Messenger / metabolism. Rats. Rats, Sprague-Dawley. Restraint, Physical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroscience. 2000;97(2):253-66 [10799757.001]
  • [Cites] Behav Brain Res. 2008 Jun 26;190(1):1-13 [18384891.001]
  • [Cites] Mol Cell Neurosci. 2001 Dec;18(6):593-605 [11749036.001]
  • [Cites] Hippocampus. 2002;12(2):245-57 [12000121.001]
  • [Cites] Neurosci Biobehav Rev. 2002 May;26(3):321-52 [12034134.001]
  • [Cites] J Neuroendocrinol. 2002 Jun;14(6):499-505 [12047725.001]
  • [Cites] Eur J Neurosci. 2004 Feb;19(3):659-66 [14984416.001]
  • [Cites] Neuroscience. 2004;125(1):1-6 [15051139.001]
  • [Cites] BMC Genomics. 2003 Jul 29;4(1):31 [12885301.001]
  • [Cites] J Neurobiol. 2004 Aug;60(2):236-48 [15266654.001]
  • [Cites] Stress. 2004 Jun;7(2):131-43 [15512858.001]
  • [Cites] J Comp Neurol. 1977 Mar 1;172(1):49-84 [65364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(16):5665-9 [2441390.001]
  • [Cites] Brain Res Bull. 1987 Dec;19(6):639-49 [2449937.001]
  • [Cites] Neuroscience. 1988 Feb;24(2):379-431 [2452377.001]
  • [Cites] J Neurobiol. 1992 Feb;23(1):71-88 [1564456.001]
  • [Cites] Brain Res. 1992 Aug 21;588(2):341-5 [1393587.001]
  • [Cites] J Neurosci. 1993 Sep;13(9):3839-47 [8396170.001]
  • [Cites] Neuron. 1993 Sep;11(3):423-31 [8398137.001]
  • [Cites] J Neurochem. 1993 Nov;61(5):1957-60 [7901339.001]
  • [Cites] Hippocampus. 1993;3 Spec No:33-44 [8287110.001]
  • [Cites] Neuroscience. 1995 Nov;69(1):83-8 [8637635.001]
  • [Cites] J Neurosci. 1996 May 15;16(10):3534-40 [8627386.001]
  • [Cites] J Comp Neurol. 1996 Jul 8;370(4):465-78 [8807448.001]
  • [Cites] J Comp Neurol. 1997 Jan 27;377(4):465-99 [9007187.001]
  • [Cites] Anal Biochem. 1997 Feb 15;245(2):154-60 [9056205.001]
  • [Cites] Nature. 1997 May 29;387(6632):497-500 [9168111.001]
  • [Cites] J Psychopharmacol. 1997;11(2):99-106 [9208373.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14002-8 [9391142.001]
  • [Cites] Ann N Y Acad Sci. 1998 May 1;840:33-44 [9629234.001]
  • [Cites] J Neurosci. 1999 Apr 1;19(7):2834-40 [10087094.001]
  • [Cites] Am J Psychiatry. 1999 Jun;156(6):837-41 [10360120.001]
  • [Cites] J Neurosci Res. 2004 Dec 1;78(5):702-10 [15505804.001]
  • [Cites] J Comp Neurol. 2005 Nov 14;492(2):145-77 [16196030.001]
  • [Cites] Cereb Cortex. 2005 Nov;15(11):1714-22 [15703248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17196-201 [16286650.001]
  • [Cites] Biol Psychiatry. 2006 Feb 1;59(3):244-51 [16140276.001]
  • [Cites] Neuroscience. 2006 Jun 30;140(2):597-606 [16600515.001]
  • [Cites] Neuroscience. 2006 Sep 29;142(1):1-20 [16887277.001]
  • [Cites] Brain Res. 2007 Aug 3;1161:56-64 [17603026.001]
  • [Cites] Neural Plast. 2007;2007:46276 [18253468.001]
  • [Cites] Brain Res. 2008 Mar 4;1197:1-12 [18241840.001]
  • [Cites] Cell Mol Neurobiol. 2008 May;28(3):331-42 [18197473.001]
  • [Cites] J Neurobiol. 2001 Nov 15;49(3):245-53 [11745662.001]
  • (PMID = 19180239.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2629568
  •  go-up   go-down


19. Fjorback AW, Müller HK, Wiborg O: Membrane glycoprotein M6B interacts with the human serotonin transporter. J Mol Neurosci; 2009 Mar;37(3):191-200
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane glycoprotein M6B interacts with the human serotonin transporter.
  • In the present study, using the yeast two-hybrid system, we identified the membrane glycoprotein M6B as a binding partner of SERT.
  • M6B belongs to a proteolipid protein family, which is expressed in neurons and in oligodendrocytes in the brain.
  • The co-expression of SERT with M6B results in a significant decrease in SERT-mediated serotonin uptake caused by a down-regulation of SERT surface expression.
  • Furthermore, we find, using confocal microscopy, that M6B co-localizes with SERT when transiently expressed in HEK-MSR-293 cells and when endogenously expressed in RN46A cells.
  • Taken together, our data suggest that M6B regulates the serotonin uptake by affecting cellular trafficking of the serotonin transporter.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Jul 30;285(5428):763-6 [10427004.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Jul 23;71(1):120-6 [10407194.001]
  • [Cites] J Neurosci Res. 2000 Oct 1;62(1):1-8 [11002282.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2542-6 [7681602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):8119-24 [17452640.001]
  • [Cites] Int J Dev Neurosci. 1997 Jun;15(3):285-93 [9253653.001]
  • [Cites] Mol Cell Neurosci. 2001 Dec;18(6):593-605 [11749036.001]
  • [Cites] Mol Interv. 2004 Apr;4(2):109-23 [15087484.001]
  • [Cites] Neuron. 2003 Oct 30;40(3):537-49 [14642278.001]
  • [Cites] Curr Drug Targets. 2006 Dec;7(12):1659-69 [17168841.001]
  • [Cites] J Neurosci. 1997 Jan 1;17(1):45-57 [8987735.001]
  • [Cites] Science. 1991 Oct 25;254(5031):579-80 [1948036.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(16):5665-9 [2441390.001]
  • [Cites] Nature. 1991 Nov 7;354(6348):66-70 [1944572.001]
  • [Cites] J Psychopharmacol. 1998;12(2):115-21 [9694022.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):297-303 [15694238.001]
  • [Cites] Biol Psychiatry. 1990 Sep 1;28(5):443-54 [2207221.001]
  • [Cites] Biochemistry. 2005 Oct 18;44(41):13612-24 [16216085.001]
  • [Cites] J Cell Biol. 2002 Apr 15;157(2):327-36 [11956232.001]
  • [Cites] Biochem Soc Trans. 2001 Nov;29(Pt 6):722-8 [11709063.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):22239-47 [17548356.001]
  • [Cites] Biochim Biophys Acta. 1993 Oct 4;1144(3):249-63 [8104483.001]
  • [Cites] Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83 [10193665.001]
  • [Cites] J Neurosci Res. 1998 Jun 15;52(6):633-40 [9669312.001]
  • [Cites] Nature. 2005 Sep 8;437(7056):215-23 [16041361.001]
  • [Cites] Trends Neurosci. 1992 Jul;15(7):265-8 [1381123.001]
  • [Cites] FEBS Lett. 2004 May 7;565(1-3):1-5 [15135042.001]
  • [Cites] J Biol Chem. 2006 Sep 29;281(39):28901-9 [16870614.001]
  • [Cites] Eur J Neurosci. 2006 Dec;24(11):3141-52 [17156375.001]
  • [Cites] J Neurochem. 2006 Apr;97 Suppl 1:3-10 [16635244.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38770-8 [15226315.001]
  • [Cites] J Comp Neurol. 1996 Jul 8;370(4):465-78 [8807448.001]
  • [Cites] J Am Chem Soc. 2008 Mar 26;130(12):3853-65 [18314975.001]
  • [Cites] J Neurobiol. 1996 Feb;29(2):138-50 [8821173.001]
  • [Cites] Eur J Neurosci. 2006 Jul;24(1):55-64 [16882008.001]
  • [Cites] Am J Med Genet A. 2004 Jul 15;128A(2):156-8 [15214007.001]
  • (PMID = 18581270.001).
  • [ISSN] 0895-8696
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPM6A protein, human; 0 / GPM6B protein, human; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Serotonin Plasma Membrane Transport Proteins; 333DO1RDJY / Serotonin
  •  go-up   go-down


20. Ueda A, Wood TK: Connecting quorum sensing, c-di-GMP, pel polysaccharide, and biofilm formation in Pseudomonas aeruginosa through tyrosine phosphatase TpbA (PA3885). PLoS Pathog; 2009 Jun;5(6):e1000483
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connecting quorum sensing, c-di-GMP, pel polysaccharide, and biofilm formation in Pseudomonas aeruginosa through tyrosine phosphatase TpbA (PA3885).
  • This screen identified the PA3885 mutant, which had 147-fold more biofilm than the wild-type strain.
  • Whole transcriptome analysis showed that loss of PA3885 activated expression of the pel locus, an operon that encodes for the synthesis of extracellular matrix polysaccharide.
  • Genetic screening identified that loss of PelABDEG and the PA1120 protein (which contains a GGDEF-motif) suppressed the phenotypes of the PA3885 mutant, suggesting that the function of the PA3885 protein is to regulate 3,5-cyclic diguanylic acid (c-di-GMP) concentrations as a phosphatase since c-di-GMP enhances biofilm formation by activating PelD, and c-di-GMP inhibits swarming.
  • Loss of PA3885 protein increased cellular c-di-GMP concentrations; hence, PA3885 protein is a negative regulator of c-di-GMP production.
  • Las-mediated quorum sensing positively regulates expression of the PA3885 gene.
  • These results show that the PA3885 protein responds to AHL signals and likely dephosphorylates PA1120, which leads to reduced c-di-GMP production.
  • This inhibits matrix exopolysaccharide formation, which leads to reduced biofilm formation; hence, we provide a mechanism for quorum sensing control of biofilm formation through the pel locus and suggest PA3885 should be named TpbA for tyrosine phosphatase related to biofilm formation and PA1120 should be TpbB.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 2007 Nov;189(22):8154-64 [17586642.001]
  • [Cites] Curr Opin Microbiol. 2007 Dec;10(6):644-8 [17981495.001]
  • [Cites] J Bacteriol. 2008 Apr;190(8):2671-9 [18245294.001]
  • [Cites] J Biol Chem. 2008 Apr 11;283(15):9933-44 [18256026.001]
  • [Cites] Appl Microbiol Biotechnol. 2008 Jul;79(5):843-58 [18481058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13904-9 [10570171.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):959-64 [10984043.001]
  • [Cites] J Bacteriol. 2000 Nov;182(21):5990-6 [11029417.001]
  • [Cites] Trends Microbiol. 2000 Nov;8(11):498-504 [11121759.001]
  • [Cites] Mol Microbiol. 2002 Feb;43(3):809-21 [11929534.001]
  • [Cites] Clin Microbiol Rev. 2002 Apr;15(2):155-66 [11932228.001]
  • [Cites] Mol Microbiol. 2002 Oct;46(2):571-86 [12406230.001]
  • [Cites] J Bacteriol. 2003 Feb;185(3):1027-36 [12533479.001]
  • [Cites] J Bacteriol. 2003 Apr;185(7):2080-95 [12644477.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13627-32 [12556522.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14429-41 [12562757.001]
  • [Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]
  • [Cites] Arch Microbiol. 2004 Mar;181(3):171-81 [14745484.001]
  • [Cites] Appl Microbiol Biotechnol. 2004 May;64(4):515-24 [14727089.001]
  • [Cites] J Bacteriol. 2004 Jul;186(14):4466-75 [15231778.001]
  • [Cites] Mol Microbiol. 2004 Aug;53(4):1075-87 [15306012.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Apr;76(4):1648-52 [377280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7347-51 [7012838.001]
  • [Cites] J Bacteriol. 1986 Mar;165(3):1002-10 [3005231.001]
  • [Cites] J Biol Chem. 1990 Nov 5;265(31):18933-43 [2172238.001]
  • [Cites] Methods Enzymol. 1991;201:477-82 [1943774.001]
  • [Cites] Science. 1993 May 21;260(5111):1127-30 [8493556.001]
  • [Cites] Annu Rev Microbiol. 1993;47:597-626 [8257110.001]
  • [Cites] J Bacteriol. 1995 Feb;177(3):654-9 [7836299.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5910-4 [7597052.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6424-8 [7604006.001]
  • [Cites] Mol Microbiol. 2008 Jul;69(2):376-89 [18485075.001]
  • [Cites] Mol Microbiol. 2008 Sep;69(5):1153-64 [18573179.001]
  • [Cites] J Mol Biol. 2008 Nov 7;383(2):414-23 [18775435.001]
  • [Cites] Trends Microbiol. 2008 Oct;16(10):496-506 [18775660.001]
  • [Cites] J Bacteriol. 2009 Jan;191(1):169-77 [18952786.001]
  • [Cites] Microb Biotechnol. 2009 Jan;2(1):62-74 [21261882.001]
  • [Cites] Proteins. 1991;11(2):95-110 [1946347.001]
  • [Cites] Biochem J. 1995 Nov 1;311 ( Pt 3):921-7 [7487952.001]
  • [Cites] J Biochem. 1996 Dec;120(6):1055-63 [9010748.001]
  • [Cites] J Bacteriol. 1997 May;179(10):3127-32 [9150205.001]
  • [Cites] Science. 1998 Apr 10;280(5361):295-8 [9535661.001]
  • [Cites] Bioinformatics. 1998;14(4):378-9 [9632836.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 1998;27:133-64 [9646865.001]
  • [Cites] Mol Microbiol. 1998 Oct;30(2):285-93 [9791174.001]
  • [Cites] Mol Microbiol. 1998 Oct;30(2):295-304 [9791175.001]
  • [Cites] J Bacteriol. 1998 Dec;180(23):6384-8 [9829950.001]
  • [Cites] Biotechnol Bioeng. 2004 Dec 5;88(5):630-42 [15470704.001]
  • [Cites] Mol Microbiol. 2005 Jan;55(2):368-80 [15659157.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):1954-63 [15784535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14422-7 [16186483.001]
  • [Cites] J Microbiol. 2005 Oct;43(5):443-50 [16273037.001]
  • [Cites] J Bacteriol. 2006 Jan;188(1):305-16 [16352847.001]
  • [Cites] J Mol Microbiol Biotechnol. 2005;9(3-4):125-31 [16415586.001]
  • [Cites] Int J Med Microbiol. 2006 Apr;296(2-3):83-91 [16483840.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):8090-9 [16418169.001]
  • [Cites] Curr Opin Microbiol. 2006 Apr;9(2):218-28 [16530465.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2833-8 [16477005.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2839-44 [16477007.001]
  • [Cites] Microbiology. 2006 Jun;152(Pt 6):1679-86 [16735731.001]
  • [Cites] DNA Res. 2005;12(5):291-9 [16769691.001]
  • [Cites] Appl Environ Microbiol. 2006 Jul;72(7):5027-36 [16820502.001]
  • [Cites] J Bacteriol. 2007 May;189(9):3603-12 [17337585.001]
  • [Cites] J Bacteriol. 2007 Jul;189(14):5383-6 [17496081.001]
  • [Cites] Nat Cell Biol. 2007 Jul;9(7):797-803 [17558395.001]
  • [Cites] J Bacteriol. 2007 Sep;189(18):6695-703 [17631636.001]
  • [Cites] Environ Microbiol. 2007 Oct;9(10):2475-85 [17803773.001]
  • [Cites] Mol Microbiol. 2007 Sep;65(6):1474-84 [17824927.001]
  • [Cites] J Bacteriol. 2007 Nov;189(22):8165-78 [17586641.001]
  • (PMID = 19543378.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB003872
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Bacterial Proteins; 0 / Glycolipids; 0 / Polysaccharides, Bacterial; 0 / rhamnolipid; 42HK56048U / Tyrosine; 61093-23-0 / bis(3',5')-cyclic diguanylic acid; EC 3.1.3.48 / Protein Tyrosine Phosphatases; H2D2X058MU / Cyclic GMP
  • [Other-IDs] NLM/ PMC2691606
  •  go-up   go-down


21. Huang G, Dong R, Allen R, Davis EL, Baum TJ, Hussey RS: Developmental expression and molecular analysis of two Meloidogyne incognita pectate lyase genes. Int J Parasitol; 2005 May;35(6):685-92
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developmental expression and molecular analysis of two Meloidogyne incognita pectate lyase genes.
  • Two cDNAs (designated Mi-pel-1 and Mi-pel-2) encoding pectate lyases were isolated from the root-knot nematode, Meloidogyne incognita, oesophageal gland-cell subtractive cDNA libraries, and the corresponding genomic DNAs were subsequently cloned.
  • Southern blot analyses revealed that homologues to these pectate lyase genes were broadly distributed in Meloidogyne species, and present as members of a small multigene family.
  • Mi-pel-1 and Mi-pel-2 encoded, respectively, predicted proteins of 271 and 280 amino acids, each of which was preceded by a signal peptide for secretion.
  • Interestingly, these pectate lyases showed diversity at the amino acid level, with only 31% identity and 49% similarity.
  • These pectate lyases were classified into the same family of pectate lyases with those of other phytoparasitic nematodes that contain four conserved regions characteristic of the class III pectate lyases of microbes.
  • In situ mRNA hybridisation analyses showed the transcripts of Mi-pel-1 and Mi-pel-2 accumulated exclusively within the subventral oesophageal gland cells of M. incognita.
  • These results indicated that these pectate lyases, like cellulases, could be secreted into plant tissues to facilitate the penetration and intercellular migration of M. incognita during the early stages of plant parasitism.
  • [MeSH-major] Gene Expression Regulation, Developmental / genetics. Polysaccharide-Lyases / genetics. Tylenchoidea / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Blotting, Southern / methods. Cloning, Molecular / methods. DNA, Circular / genetics. DNA, Helminth / genetics. Genes, Helminth / genetics. In Situ Hybridization / methods. Molecular Sequence Data. Phylogeny. Reverse Transcriptase Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15862581.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF527788/ AY327873/ AY515702/ AY515703
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Circular; 0 / DNA, Helminth; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


22. Richetta A, Amoruso GF, Ascoli V, Natale ME, Carboni V, Carlomagno V, Pezza M, Cimillo M, Maiani E, Mattozzi C, Calvieri S: PEL, Kaposi's sarcoma HHV8+ and idiopathic T-lymphocitopenia CD4+. Clin Ter; 2007 Mar-Apr;158(2):151-5
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEL, Kaposi's sarcoma HHV8+ and idiopathic T-lymphocitopenia CD4+.
  • We described a case report of a 36-year-old woman with a 10-year-history of idiopathic CD4+ T-lymphocitopenia and Kaposi's sarcoma HHV8+ who developed recurrent pleural effusion.
  • Laboratory and instrumental tests with morphologic, immunophenotypic and molecular analysis of pleural sediment suggest us the diagnosis of primary effusion lymphoma (PEL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17566517.001).
  • [ISSN] 0009-9074
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Alarcon F, Bourgain C, Gauthier-Villars M, Planté-Bordeneuve V, Stoppa-Lyonnet D, Bonaïti-Pellié C: PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history. Genet Epidemiol; 2009 Jul;33(5):379-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history.
  • Providing valid risk estimates of a genetic disease with variable age of onset is a major challenge for prevention strategies.
  • This article focuses on ascertainment through at least one affected and presents an estimation method based on maximum likelihood, called the Proband's phenotype exclusion likelihood or PEL for estimating age-dependent penetrance using disease status and genotypic information of family members in pedigrees unselected for family history.
  • We studied the properties of the PEL and compared with another method, the prospective likelihood, in terms of bias and efficiency in risk estimate.
  • For that purpose, family samples were simulated under various disease risk models and under various ascertainment patterns.
  • We showed that, whatever the genetic model and the ascertainment scheme, the PEL provided unbiased estimates, whereas the prospective likelihood exhibited some bias in a number of situations.
  • As an illustration, we estimated the disease risk for transthyretin amyloid neuropathy from a French sample and a Portuguese sample and for BRCA1/2 associated breast cancer from a sample ascertained on early-onset breast cancer cases.
  • [MeSH-minor] Age Factors. Amyloid Neuropathies / genetics. Bias (Epidemiology). Breast Neoplasms / genetics. France. Genes, BRCA1. Genes, BRCA2. Humans. Likelihood Functions. Models, Genetic. Models, Statistical. Pedigree. Phenotype. Portugal. Prealbumin / genetics. Risk

  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • HAL archives ouvertes. Full text from .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Wiley-Liss, Inc.
  • [Cites] Genomics. 1999 Dec 15;62(3):369-76 [10644434.001]
  • [Cites] Eur J Hum Genet. 2007 Aug;15(8):831-6 [17473834.001]
  • [Cites] J Med Genet. 2001 Jan;38(1):43-7 [11332399.001]
  • [Cites] J Med Genet. 2002 May;39(5):335-9 [12011152.001]
  • [Cites] Genet Epidemiol. 2003 Apr;24(3):173-80 [12652521.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):e120 [14627687.001]
  • [Cites] Genet Epidemiol. 2004 Sep;27(2):109-17 [15305327.001]
  • [Cites] Hum Hered. 1971;21(6):523-42 [5149961.001]
  • [Cites] Clin Genet. 1977 Oct;12(4):208-12 [334399.001]
  • [Cites] Genet Epidemiol. 1990;7(6):391-407 [2292365.001]
  • [Cites] Am J Hum Genet. 1995 Jan;56(1):265-71 [7825587.001]
  • [Cites] Am J Hum Genet. 1995 Jan;56(1):33-43 [7825595.001]
  • [Cites] Genet Epidemiol. 1995;12(1):13-25 [7713397.001]
  • [Cites] Hum Mol Genet. 1997 Jan;6(1):105-10 [9002677.001]
  • [Cites] Am J Hum Genet. 1997 May;60(5):1021-30 [9150149.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):676-89 [9497246.001]
  • [Cites] Am J Epidemiol. 1998 Oct 1;148(7):623-30 [9778168.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):939-50 [9818066.001]
  • [Cites] Genet Epidemiol. 1999;16(1):15-39 [9915565.001]
  • [Cites] Am J Hum Genet. 1959 Mar;11(1):1-16 [13626932.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):404-13 [15887246.001]
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):1119-31 [10712222.001]
  • (PMID = 19089844.001).
  • [ISSN] 1098-2272
  • [Journal-full-title] Genetic epidemiology
  • [ISO-abbreviation] Genet. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prealbumin
  • [Other-IDs] NLM/ HALMS358140; NLM/ PMC3108000
  •  go-up   go-down


24. Alfonso J, Fernández ME, Cooper B, Flugge G, Frasch AC: The stress-regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation. Proc Natl Acad Sci U S A; 2005 Nov 22;102(47):17196-201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The stress-regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation.
  • We have recently identified the glycoprotein M6a as a stress-responsive gene in the hippocampal formation.
  • This gene is down-regulated in the hippocampus of both socially and physically stressed animals, and this effect can be reversed by antidepressant treatment.
  • In the present work, we analyzed the biological function of the M6a protein.
  • Immunohistochemistry showed that the M6a protein is abundant in all hippocampal subregions, and subcellular analysis in primary hippocampal neurons revealed its presence in membrane protrusions (filopodia/spines).
  • Transfection experiments revealed that M6a overexpression induces neurite formation and increases filopodia density in hippocampal neurons.
  • M6a knockdown with small interference RNA methodology showed that M6a low-expressing neurons display decreased filopodia number and a lower density of synaptophysin clusters.
  • Taken together, our findings indicate that M6a plays an important role in neurite/filopodium outgrowth and synapse formation.
  • Therefore, reduced M6a expression might be responsible for the morphological alterations found in the hippocampus of chronically stressed animals.
  • Potential mechanisms that might explain the biological effects of M6a are discussed.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 1996 Jul;17(1):91-102 [8755481.001]
  • [Cites] J Neurosci. 1996 May 15;16(10):3534-40 [8627386.001]
  • [Cites] Science. 1998 Jan 23;279(5350):509-14 [9438836.001]
  • [Cites] Psychopharmacology (Berl). 1997 Dec;134(4):319-29 [9452163.001]
  • [Cites] J Neurosci. 1998 Nov 1;18(21):8900-11 [9786995.001]
  • [Cites] Annu Rev Neurosci. 1999;22:105-22 [10202533.001]
  • [Cites] Am J Psychiatry. 1999 Jun;156(6):837-41 [10360120.001]
  • [Cites] J Cell Biol. 1999 Jun 14;145(6):1265-75 [10366598.001]
  • [Cites] J Neurocytol. 1998 Sep;27(9):695-703 [10447243.001]
  • [Cites] Prog Brain Res. 2005;147:29-37 [15581695.001]
  • [Cites] Neuroscience. 2005;131(1):43-54 [15680690.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13438-43 [10557339.001]
  • [Cites] Neuroscience. 2000;97(2):253-66 [10799757.001]
  • [Cites] Brain Res. 2000 Oct 13;880(1-2):147-58 [11032999.001]
  • [Cites] Biol Psychiatry. 2000 Oct 15;48(8):721-31 [11063969.001]
  • [Cites] Hippocampus. 2000;10(5):582-6 [11075828.001]
  • [Cites] Nat Rev Neurosci. 2000 Dec;1(3):173-80 [11257905.001]
  • [Cites] J Neurosci. 2001 Jul 15;21(14):5169-81 [11438592.001]
  • [Cites] J Neurosci. 2001 Aug 15;21(16):6105-14 [11487634.001]
  • [Cites] J Neurosci. 2001 Aug 15;21(16):6292-7 [11487652.001]
  • [Cites] Pharmacol Biochem Behav. 2002 Aug;73(1):247-58 [12076743.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7398-407 [12196561.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):722-8 [12359212.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:601-35 [12142283.001]
  • [Cites] Hippocampus. 2002;12(5):585-91 [12440574.001]
  • [Cites] J Neurosci. 2003 Jan 15;23(2):659-65 [12533625.001]
  • [Cites] Neuron. 2003 Jan 23;37(2):263-74 [12546821.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(11):2447-56 [12814376.001]
  • [Cites] Rev Neurosci. 2003;14(3):233-40 [14513866.001]
  • [Cites] Neuron. 2003 Oct 9;40(2):243-64 [14556707.001]
  • [Cites] J Neurosci Res. 2003 Dec 1;74(5):744-53 [14635225.001]
  • [Cites] Eur J Neurosci. 2004 Feb;19(3):659-66 [14984416.001]
  • [Cites] Curr Opin Pharmacol. 2004 Feb;4(1):58-64 [15018840.001]
  • [Cites] Neuron. 2004 Oct 14;44(2):321-34 [15473970.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):782-8 [15483599.001]
  • [Cites] J Neurosci. 1991 Jun;11(6):1617-26 [1904480.001]
  • [Cites] J Neurobiol. 1992 Feb;23(1):71-88 [1564456.001]
  • [Cites] Brain Res. 1992 Aug 21;588(2):341-5 [1393587.001]
  • [Cites] Neuron. 1993 Sep;11(3):423-31 [8398137.001]
  • [Cites] Arch Gen Psychiatry. 1997 Jul;54(7):597-606 [9236543.001]
  • (PMID = 16286650.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC1287971
  •  go-up   go-down


25. Feng L, Musto CJ, Kemling JW, Lim SH, Suslick KS: A colorimetric sensor array for identification of toxic gases below permissible exposure limits. Chem Commun (Camb); 2010 Mar 28;46(12):2037-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A colorimetric sensor array for identification of toxic gases below permissible exposure limits.
  • A colorimetric sensor array has been developed for the rapid and sensitive detection of 20 toxic industrial chemicals (TICs) at their PELs (permissible exposure limits).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Mater. 2003 Jan;2(1):19-24 [12652667.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):710-3 [10963592.001]
  • [Cites] Anal Chem. 2009 Aug 1;81(15):6526-33 [20337402.001]
  • [Cites] Anal Chem. 2009 Jul 1;81(13):5281-90 [19563211.001]
  • [Cites] Org Lett. 2008 Oct 16;10(20):4405-8 [18783231.001]
  • [Cites] Nat Chem. 2009 Oct;1(7):562-7 [20160982.001]
  • [Cites] Anal Chem. 2006 Jun 1;78(11):3591-600 [16737212.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jul 18;44(29):4528-32 [16003792.001]
  • [Cites] MRS Bull. 2004 Oct;29(10):720-5 [15991401.001]
  • [Cites] Acc Chem Res. 2004 Sep;37(9):663-72 [15379582.001]
  • [Cites] J Org Chem. 2007 Feb 2;72(3):687-99 [17253783.001]
  • (PMID = 20221484.001).
  • [ISSN] 1364-548X
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / U01 ES016011; United States / NIEHS NIH HHS / ES / U01 ES016011-04; United States / NIEHS NIH HHS / ES / U01ES016011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gases
  • [Other-IDs] NLM/ NIHMS229286; NLM/ PMC2976522
  •  go-up   go-down


26. Wong SS, Thomas A, Barbaris B, Lantz RC, Witten ML: Pulmonary evaluation of permissible exposure limit of syntroleum S-8 synthetic jet fuel in mice. Toxicol Sci; 2009 Jun;109(2):312-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary evaluation of permissible exposure limit of syntroleum S-8 synthetic jet fuel in mice.
  • No significant changes in respiratory permeability were exhibited, indicating that there was no loss of epithelial barrier integrity following S-8 exposure.
  • However, morphological examination and morphometric analysis of distal lung tissue, by using transmission electron microscopy, revealed cellular damage in alveolar type II epithelial cells, with significant increases in volume density of lamellar bodies/vacuoles at 352 and 616 S-8 mg/m(3).
  • Moreover, terminal bronchiolar Clara injury, as evidenced by apical membrane blebs, was observed at relatively low concentrations, suggesting if this synthetic jet fuel is utilized, the current permissible exposure limit of 350 mg/m(3) for hydrocarbon fuels should cautiously be applied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Pathol. 2000 Sep-Oct;28(5):656-63 [11026600.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3659-69 [10612293.001]
  • [Cites] Toxicol Ind Health. 2001 Feb;17(1):23-9 [12004922.001]
  • [Cites] Toxicology. 2002 Jun 14;175(1-3):235-45 [12049851.001]
  • [Cites] Toxicol Sci. 2003 Dec;76(2):347-56 [14514957.001]
  • [Cites] Toxicology. 2004 Apr 15;197(2):139-47 [15003324.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):301-8 [15093277.001]
  • [Cites] J Toxicol Environ Health A. 2004 Jul 23;67(14):1109-29 [15205027.001]
  • [Cites] Toxicol Appl Pharmacol. 1984 Aug;75(1):44-51 [6464021.001]
  • [Cites] Scand J Work Environ Health. 1985 Dec;11(6):433-7 [4095521.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):454-64 [3717299.001]
  • [Cites] Hepatology. 1995 May;21(5):1361-72 [7737643.001]
  • [Cites] J Appl Toxicol. 1996 May-Jun;16(3):197-200 [8818858.001]
  • [Cites] Toxicol Ind Health. 1997 Jan-Feb;13(1):43-55 [9098949.001]
  • [Cites] J Occup Environ Med. 1997 Jul;39(7):623-32 [9253723.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):L229-38 [9950884.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jul;21(1):44-53 [10385592.001]
  • [Cites] Toxicol Sci. 1999 Sep;51(1):119-25 [10496683.001]
  • [Cites] J Chromatogr A. 2005 Nov 4;1093(1-2):11-20 [16233866.001]
  • [Cites] Environ Health Perspect. 2006 Feb;114(2):182-5 [16451852.001]
  • [Cites] J Toxicol Sci. 2006 Aug;31(3):219-28 [16960432.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Oct;35(4):479-87 [16690985.001]
  • [Cites] Int J Toxicol. 2007 Jul-Aug;26(4):325-9 [17661223.001]
  • [Cites] Toxicol Sci. 2007 Dec;100(2):415-22 [17890764.001]
  • [Cites] J Appl Toxicol. 2008 May;28(4):543-53 [17966119.001]
  • [Cites] Toxicology. 2008 Dec 5;254(1-2):106-11 [18930109.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 Jul;15(1):1-8 [8679213.001]
  • [Cites] Toxicol Sci. 2000 Dec;58(2):290-8 [11099641.001]
  • (PMID = 19357071.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NIEHS NIH HHS / ES / ES06694
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydrocarbons; 0 / S-8 fuel
  • [Other-IDs] NLM/ PMC2683924
  •  go-up   go-down


27. Arguello M, Paz S, Hernandez E, Corriveau-Bourque C, Fawaz LM, Hiscott J, Lin R: Leukotriene A4 hydrolase expression in PEL cells is regulated at the transcriptional level and leads to increased leukotriene B4 production. J Immunol; 2006 Jun 1;176(11):7051-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukotriene A4 hydrolase expression in PEL cells is regulated at the transcriptional level and leads to increased leukotriene B4 production.
  • Primary effusion lymphoma (PEL) is a herpesvirus-8-associated lymphoproliferative disease characterized by migration of tumor cells to serous body cavities.
  • PEL cells originate from postgerminal center B cells and share a remarkable alteration in B cell transcription factor expression and/or activation with classical Hodgkin's disease cells.
  • Comparative analysis of gene expression by cDNA microarray of BCBL-1 cells (PEL), L-428 (classical Hodgkin's disease), and BJAB cells revealed a subset of genes that were differentially expressed in BCBL-1 cells.
  • Among these, four genes involved in cell migration and chemotaxis were strongly up-regulated in PEL cells: leukotriene A4 (LTA4) hydrolase (LTA4H), IL-16, thrombospondin-1 (TSP-1), and selectin-P ligand (PSGL-1).
  • Up-regulation of LTA4H was investigated at the transcriptional level.
  • Formation of a specific DNA-protein complex in this region was confirmed by EMSA.
  • [MeSH-minor] Cell Line, Tumor. Enzyme Activation / genetics. Gene Expression Profiling. Hodgkin Disease / genetics. Humans. Inflammation / genetics. Inflammation / immunology. Interleukin-16 / physiology. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / genetics. Membrane Glycoproteins / physiology. Promoter Regions, Genetic. RNA, Messenger / biosynthesis. Thrombospondin 1 / biosynthesis. Thrombospondin 1 / genetics. Thrombospondin 1 / physiology. Transcription, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709867.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-16; 0 / Membrane Glycoproteins; 0 / P-selectin ligand protein; 0 / RNA, Messenger; 0 / Thrombospondin 1; 1HGW4DR56D / Leukotriene B4; EC 3.3.2.- / Epoxide Hydrolases; EC 3.3.2.- / leukotriene A4 hydrolase
  •  go-up   go-down


28. Ueda K, Ito E, Karayama M, Ohsaki E, Nakano K, Watanabe S: KSHV-infected PEL cell lines exhibit a distinct gene expression profile. Biochem Biophys Res Commun; 2010 Apr 9;394(3):482-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV-infected PEL cell lines exhibit a distinct gene expression profile.
  • We analyzed the gene expression profiles of lymphocyte-originated tumor cell lines - primary effusion lymphoma (PEL) cell lines, T-cell leukemia (TCL) cell lines, Burkitt lymphoma (BL) cell lines - and two sets of normal peripheral blood mononuclear cells (PBMCs) - in order to determine characteristic gene expression profiles for each of the former three groups.
  • And we found that these cell lines showed respective typical gene expression profiles and classified into clear four groups, PEL, TCL, BL, and normal PBMCs.
  • Two B lymphocyte-originated tumor cell lines, PEL and BL cell lines, clearly exhibited distinct gene expression profiles, respectively.
  • Even though there was only one line that was co-infected with both Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), KSHV seemed to govern the gene expression profile of the co-infected line.
  • These data suggested not only that established typical tumor cell lines show a distinct gene expression profile but also that this profile may be governed by certain viruses.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Lymphoma, Primary Effusion / genetics. Lymphoma, Primary Effusion / virology
  • [MeSH-minor] Angiopoietin-1 / genetics. Cell Line, Tumor. Gene Expression Profiling. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20175997.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-1
  •  go-up   go-down


29. Radlińska M, Piekarowicz A, Galimand M, Bujnicki JM: Cloning and preliminary characterization of a GATC-specific beta2-class DNA:m6A methyltransferase encoded by transposon Tn1549 from Enterococcus spp. Pol J Microbiol; 2005;54(3):249-52
REBASE - The Restriction Enzyme Database. gene/protein/disease-specific - REBASE ref# 9191 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cloning and preliminary characterization of a GATC-specific beta2-class DNA:m6A methyltransferase encoded by transposon Tn1549 from Enterococcus spp.
  • A recent study revealed a subfamily of N6-adenine (m6A) methyltransferases that comprises a few functionally studied eukaryotic members acting on mRNA and prokaryotic members acting on DNA as well as numerous uncharacterized open reading frames.
  • Here, we report cloning and functional characterization of a prokaryotic member of this family encoded by transposon Tn1549 from Enterococcus spp.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16450842.001).
  • [ISSN] 1733-1331
  • [Journal-full-title] Polish journal of microbiology
  • [ISO-abbreviation] Pol. J. Microbiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DNA Transposable Elements; 0 / DNA, Bacterial; EC 2.1.1.72 / Site-Specific DNA-Methyltransferase (Adenine-Specific)
  •  go-up   go-down


30. Metaxa-Mariatou V, Papaioannou D, Loli A, Papadopoulou I, Gazouli M, Mavroudis P, Nasioulas G: Subtype C1 persistent infection of HHV-8 in a PEL patient. Leuk Lymphoma; 2005 Oct;46(10):1507-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtype C1 persistent infection of HHV-8 in a PEL patient.
  • PEL, a rare type of lymphoma constituting less than 5% of NHLs, has been recently identified as a distinct clinical and pathological entity among the B-cell lymphomas, with characteristic morphologic, immunophenotypic, molecular and viral features.
  • Using a combination of clinical, morphological, immunohistochemical features and molecular biology techniques in this study we document a PEL case with persistent HHV-8 of genotype C1 infection.
  • [MeSH-minor] Adult. Amino Acid Sequence. Base Sequence. Follow-Up Studies. Genotype. Greece / ethnology. Hodgkin Disease. Humans. Male. Molecular Sequence Data. Phylogeny. Sequence Alignment. Viral Proteins / chemistry. Viral Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194897.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / K1 protein, Human herpesvirus 8; 0 / Viral Proteins
  •  go-up   go-down


31. Liao CH, Fett W, Tzean SS, Hoffman G: Detection and sequence analysis of an altered pectate lyase gene in Pseudomonas syringae pv. glycinea and related bacteria. Can J Microbiol; 2006 Nov;52(11):1051-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and sequence analysis of an altered pectate lyase gene in Pseudomonas syringae pv. glycinea and related bacteria.
  • Pectate lyase (PL) is a potent cell wall-degrading enzyme known to play a role in the microbial infection of plants.
  • However, the PL gene (pel) was detected by Southern hybridization in four out of four P. syringae pv. glycinea strains examined.
  • A P. syringae pv. glycinea pel gene was cloned, sequenced, and predicted to encode a protein sharing 70%-90% identity in amino acid sequence with PLs produced by pectolytic pseudomonads and xanthomonads.
  • A series of amino acid and nucleotide sequence analyses reveal that (i) the predicted P. syringae pv. glycinea PL contains two regions in the amino acid sequence that may affect the formation of a beta-helix structure important for the enzyme activity, and (ii) the P. syringae pv. glycinea pel gene contains a single-base insertion, a double-base insertion, and an 18-bp deletion, which can lead to the synthesis of an inactive PL protein.
  • The altered pel sequence was also detected by polymerase chain reaction and nucleotide sequencing in the genomes of other pathovars of P. syringae, including phaseolicola and tagetis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17215896.001).
  • [ISSN] 0008-4166
  • [Journal-full-title] Canadian journal of microbiology
  • [ISO-abbreviation] Can. J. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


32. Lautier T, Blot N, Muskhelishvili G, Nasser W: Integration of two essential virulence modulating signals at the Erwinia chrysanthemi pel gene promoters: a role for Fis in the growth-phase regulation. Mol Microbiol; 2007 Dec;66(6):1491-505
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of two essential virulence modulating signals at the Erwinia chrysanthemi pel gene promoters: a role for Fis in the growth-phase regulation.
  • Production of the essential virulence factors, called pectate lyases (Pels), in the phytopathogenic bacterium Erwinia chrysanthemi is controlled by a complex regulation system and responds to various stimuli, such as the presence of pectin or plant extracts, growth phase, temperature and iron concentration.
  • Eight regulators modulating the expression of the pel genes (encoding Pels) have been characterized.
  • Although many studies have been carried out, the mechanisms of control of Pel production by growth phase have not yet been elucidated.
  • Here we report that a fis mutant of E. chrysanthemi showed a strong increase in transcription of the pel genes during exponential growth whereas induction of expression in the parental strain occurred at the end of exponential growth.
  • This reveals that Fis acts to prevent an efficient transcription of pel genes at the beginning of exponential growth and also provides evidence of the involvement of Fis in the growth-phase regulation of the pel genes.
  • By using in vitro DNA-protein interactions and transcription experiments, we find that Fis directly represses the pel gene expression at the transcription initiation step.
  • In addition, we show that Fis acts in concert with KdgR, the main repressor responding to the presence of pectin compounds, to shut down the pel gene transcription.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028312.001).
  • [ISSN] 0950-382X
  • [Journal-full-title] Molecular microbiology
  • [ISO-abbreviation] Mol. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / KdgR protein, Erwinia chrysanthemi; 0 / Repressor Proteins; 0 / Transcription Factors; 9007-49-2 / DNA; EC 4.2.2.- / PelE protein, Erwinia chrysanthemi; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


33. Santiago-Doménech N, Jiménez-Bemúdez S, Matas AJ, Rose JK, Muñoz-Blanco J, Mercado JA, Quesada MA: Antisense inhibition of a pectate lyase gene supports a role for pectin depolymerization in strawberry fruit softening. J Exp Bot; 2008;59(10):2769-79
Hazardous Substances Data Bank. PECTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense inhibition of a pectate lyase gene supports a role for pectin depolymerization in strawberry fruit softening.
  • It has been reported previously that inhibiting the expression of pectate lyase genes by antisense technology in strawberry (Fragaria x ananassa Duch.) fruit resulted in prolonged fruit firmness.
  • In this present study, three independent transgenic lines were identified exhibiting a greater than 90% reduction in pectate lyase transcript abundance.
  • These results indicate that pectate lyase plays an important degradative role in the primary wall and middle lamella in ripening strawberry fruit, and should be included in synergistic models of cell wall disassembly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Bot. 2001 Aug;52(361):1635-45 [11479328.001]
  • [Cites] Plant Mol Biol. 2001 Sep;47(1-2):311-40 [11554479.001]
  • [Cites] Planta. 2001 Nov;214(1):11-21 [11762160.001]
  • [Cites] Planta. 2001 Dec;214(2):257-64 [11800390.001]
  • [Cites] Plant Physiol. 2002 Feb;128(2):751-9 [11842178.001]
  • [Cites] J Exp Bot. 2002 Oct;53(377):2115-9 [12324535.001]
  • [Cites] Plant Physiol. 2007 Aug;144(4):1693-6 [17687051.001]
  • [Cites] Planta. 2003 Oct;217(6):951-61 [12838420.001]
  • [Cites] Plant Physiol. 1997 Jul;114(3):1071-6 [9232883.001]
  • [Cites] Plant Mol Biol. 1997 Aug;34(6):867-77 [9290639.001]
  • [Cites] Anal Biochem. 1998 Mar 15;257(2):107-11 [9514779.001]
  • [Cites] Plant Physiol Biochem. 2004 Dec;42(10):823-31 [15596102.001]
  • [Cites] Plant Physiol. 2007 Jun;144(2):1012-28 [17449643.001]
  • [Cites] J Exp Bot. 2003 Feb;54(383):633-45 [12554706.001]
  • (PMID = 18522930.001).
  • [ISSN] 1460-2431
  • [Journal-full-title] Journal of experimental botany
  • [ISO-abbreviation] J. Exp. Bot.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pectins; 0 / Plant Proteins; 9000-69-5 / pectin; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  • [Other-IDs] NLM/ PMC2486476
  • [Keywords] NOTNLM ; Cell wall / Fragaria / fruit ripening / pectate lyase / pectinases / strawberry
  •  go-up   go-down


34. Zhuge B, Du GC, Shen W, Zhuge J, Chen J: Efficient secretory expression of an alkaline pectate lyase gene from Bacillus subtilis in E. coli and the purification and characterization of the protein. Biotechnol Lett; 2007 Mar;29(3):405-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient secretory expression of an alkaline pectate lyase gene from Bacillus subtilis in E. coli and the purification and characterization of the protein.
  • The gene encoding pectate lyase (PL) from Bacillus subtilis WSHB04-02 was amplified by PCR, fused with a periplasmic secretion signal peptide sequence, pelB, from pET22b(+), cloned and expressed in Escherichia coli cells using a temperature control vector, pHsh.
  • [MeSH-minor] Enzyme Activation. Enzyme Stability. Gene Expression Regulation, Bacterial / physiology. Gene Expression Regulation, Enzymologic / physiology. Genetic Enhancement / methods. Recombinant Proteins / biosynthesis. Recombinant Proteins / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237974.001).
  • [ISSN] 1573-6776
  • [Journal-full-title] Biotechnology letters
  • [ISO-abbreviation] Biotechnol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


35. Srinivas U, Kumar R, Pati H, Saxena R, Tyagi S: Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify? Hematology; 2007 Oct;12(5):381-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify?
  • The clinico-hematological profile of 40 cases of acute erythroleukemia (AEL) was evaluated.
  • These were subclassified into three types, namely AML M6a, M6b and M6c based on the myeloblast and proerythroblast percentages.
  • As AEL is biologically an "erythroid predominant" disease, two ratios (PE/MB, PE/TEC) with proerythroblasts as numerator have been formulated.
  • An attempt has been made to assess the difference in these ratios in subclassified AEL.
  • There were 29 M6a, 2M6b,and 9 M6 c patients, which were subclassified using the criteria proposed by Mazzella et al.
  • The incidence of AEL in our study was 3.7%, predominantly affecting males with a predilection to younger age in contrast to Western studies.
  • Both PE/MB and PE/TEC ratios were higher in M6b and M6c in comparison to M6a.
  • The subclassification of AEL becomes essential especially in the era of lineage-targeted therapies, which can lead to the development and use of erythroid specific treatments in the near future.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / classification
  • [MeSH-minor] Adult. Age Factors. Aged. Cell Count. Erythroblasts. Erythroid Cells. Female. Granulocyte Precursor Cells. Humans. Incidence. Male. Middle Aged. Sex Factors

  • Genetic Alliance. consumer health - Acute Erythroleukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852448.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Palusa SG, Golovkin M, Shin SB, Richardson DN, Reddy AS: Organ-specific, developmental, hormonal and stress regulation of expression of putative pectate lyase genes in Arabidopsis. New Phytol; 2007;174(3):537-50
The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ-specific, developmental, hormonal and stress regulation of expression of putative pectate lyase genes in Arabidopsis.
  • Pectate lyases catalyse the eliminative cleavage of de-esterified homogalacturonan in pectin, a major component of the primary cell walls in higher plants.
  • In the completed genome of Arabidopsis, there are 26 genes (AtPLLs) that encode pectate lyase-like proteins.
  • Interestingly, all PLL genes are expressed in flowers.
  • Analysis of expression of all PLL genes in seedlings treated with hormones, abiotic stresses and elicitors of defense responses revealed significant changes in the expression of some PLLs without affecting the other PLLs.
  • The stability of transcripts of PLLs varied considerably among different genes.
  • [MeSH-major] Arabidopsis / genetics. Arabidopsis Proteins / genetics. Gene Expression Regulation, Plant. Polysaccharide-Lyases / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447910.001).
  • [ISSN] 0028-646X
  • [Journal-full-title] The New phytologist
  • [ISO-abbreviation] New Phytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arabidopsis Proteins; 0 / Deoxyadenosines; 0 / RNA, Messenger; 73-03-0 / cordycepin; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


37. Mack AA, Sugden B: EBV is necessary for proliferation of dually infected primary effusion lymphoma cells. Cancer Res; 2008 Sep 1;68(17):6963-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are found together in approximately 80% of primary effusion lymphomas (PEL), but their contribution to these cancers is unclear.
  • We found that dominant-negative derivatives of EBNA1 inhibited EBV-positive PEL cells from forming colonies.
  • Those rare PEL cells that proliferated after expression of the dominant-negative derivatives usually expressed these derivatives at low or undetectable levels and continued to maintain their EBV genomes.
  • Those proliferating cells expressing higher levels of the derivatives expressed mutant derivatives that could not bind DNA.
  • These findings indicate that EBV is required to sustain proliferation, as measured by colony formation of dually infected PEL cells.
  • Surprisingly, they did inhibit the colony-forming ability of EBV-negative, KSHV-positive PEL cells.
  • These findings indicate that the site-specific DNA-binding activity of EBNA1 or its derivatives when expressed efficiently in EBV-negative, KSHV-positive PEL cells inhibits their colony formation possibly through their binding to the KSHV genome.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] Oncogene. 2008 May 1;27(20):2833-42 [18037963.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14269-74 [14603034.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] J Virol. 1990 May;64(5):2407-10 [2157896.001]
  • [Cites] Am J Clin Pathol. 1990 Aug;94(2):170-5 [2371971.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Mod Pathol. 1995 Jan;8(1):39-45 [7731940.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Plasmid. 2007 Jul;58(1):1-12 [17350094.001]
  • [Cites] EMBO J. 2007 Oct 3;26(19):4252-62 [17853891.001]
  • [Cites] Blood. 2008 Jan 1;111(1):320-7 [17890449.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):1-22 [11960692.001]
  • (PMID = 18757410.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009135-26; United States / NCI NIH HHS / CA / CA022443-26; United States / NCI NIH HHS / CA / P01 CA022443-280004; United States / NCI NIH HHS / CA / P01 CA022443-260004; United States / NCI NIH HHS / CA / T32 CA009135-25; United States / NCI NIH HHS / CA / T32 CA09135; United States / NCI NIH HHS / CA / P01 CA022443-26; United States / NCI NIH HHS / CA / CA009135-27; United States / NCI NIH HHS / CA / P01 CA022443-270004; United States / NCI NIH HHS / CA / CA022443-270004; United States / NCI NIH HHS / CA / T32 CA009135-24; United States / NCI NIH HHS / CA / CA022443-300004; United States / NCI NIH HHS / CA / P01 CA022443-29; United States / NCI NIH HHS / CA / P01 CA022443-210004; United States / NCI NIH HHS / CA / CA022443-27; United States / NCI NIH HHS / CA / P01 CA022443-23S1; United States / NCI NIH HHS / CA / P01 CA022443-267738; United States / NCI NIH HHS / CA / CA022443-260004; United States / NCI NIH HHS / CA / P01 CA022443-220004; United States / NCI NIH HHS / CA / P01 CA022443-22; United States / NCI NIH HHS / CA / P01 CA022443-200004; United States / NCI NIH HHS / CA / P01 CA022443-300004; United States / NCI NIH HHS / CA / P01 CA022443-24; United States / NCI NIH HHS / CA / CA022443-23S1; United States / NCI NIH HHS / CA / CA009135-29; United States / NCI NIH HHS / CA / CA009135-25; United States / NCI NIH HHS / CA / P01 CA022443-290004; United States / NCI NIH HHS / CA / CA009135-26; United States / NCI NIH HHS / CA / P01 CA022443-24S10004; United States / NCI NIH HHS / CA / P01 CA022443-25; United States / NCI NIH HHS / CA / CA022443-23; United States / NCI NIH HHS / CA / CA022443-290004; United States / NCI NIH HHS / CA / CA022443-24S10004; United States / NCI NIH HHS / CA / P01 CA022443-30; United States / NCI NIH HHS / CA / T32 CA009135-28; United States / NCI NIH HHS / CA / P01 CA022443-240004; United States / NCI NIH HHS / CA / CA022443-240004; United States / NCI NIH HHS / CA / CA022443-25; United States / NCI NIH HHS / CA / T32 CA009135-31A2; United States / NCI NIH HHS / CA / P01 CA022443-250004; United States / NCI NIH HHS / CA / CA022443-23S10004; United States / NCI NIH HHS / CA / CA022443-250004; United States / NCI NIH HHS / CA / CA022443-230004; United States / NCI NIH HHS / CA / CA022443-220004; United States / NCI NIH HHS / CA / P01 CA022443-27; United States / NCI NIH HHS / CA / CA009135-24; United States / NCI NIH HHS / CA / P01 CA022443-230004; United States / NCI NIH HHS / CA / P01 CA022443-28; United States / NCI NIH HHS / CA / CA022443-24; United States / NCI NIH HHS / CA / T32 CA009135-29; United States / NCI NIH HHS / CA / CA022443-210004; United States / NCI NIH HHS / CA / CA022443-22; United States / NCI NIH HHS / CA / CA022443-29; United States / NCI NIH HHS / CA / CA022443-267738; United States / NCI NIH HHS / CA / P01 CA022443-23S10004; United States / NCI NIH HHS / CA / CA022443-280004; United States / NCI NIH HHS / CA / CA009135-30; United States / NCI NIH HHS / CA / CA009135-28; United States / NCI NIH HHS / CA / T32 CA009135-27; United States / NCI NIH HHS / CA / CA022443-24S1; United States / NCI NIH HHS / CA / CA022443-28; United States / NCI NIH HHS / CA / P01 CA022443-24S1; United States / NCI NIH HHS / CA / CA022443-200004; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / T32 CA009135; United States / NCI NIH HHS / CA / T32 CA009135-30; United States / NCI NIH HHS / CA / CA009135-31A2; United States / NCI NIH HHS / CA / P01 CA022443-23; United States / NCI NIH HHS / CA / CA22443
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens
  • [Other-IDs] NLM/ NIHMS58012; NLM/ PMC2587434
  •  go-up   go-down


38. Cohen R, Steinmaus C, Quinlan P, Ku R, Cooper M, Roberts T: Development of permissible exposure limits: the California experience. Int J Occup Environ Health; 2006 Jul-Sep;12(3):242-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of permissible exposure limits: the California experience.
  • The California OSHA Airborne Contaminant Advisory Committee reviewed several hundred substances and recommended occupational exposure limits with the intent of worker and employer protection.
  • [MeSH-major] Advisory Committees / organization & administration. Hazardous Substances / standards. Occupational Exposure / standards. Occupational Health / legislation & jurisprudence
  • [MeSH-minor] Animals. California. Communication. Humans. Maximum Allowable Concentration. National Institute for Occupational Safety and Health (U.S.) / standards. No-Observed-Adverse-Effect Level. Program Development. United States

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967831.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hazardous Substances
  •  go-up   go-down


39. Wang SA, Tang G, Fadare O, Hao S, Raza A, Woda BA, Hasserjian RP: Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol; 2008 Nov;21(11):1394-402
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification.
  • In the FAB (French-American-British) and WHO (World Heath Organization) classifications, the blasts in erythroleukemia (M6a) are enumerated from the marrow nonerythroid rather than the total-nucleated cells.
  • However, the method for blast calculation in erythroid-predominant myelodysplastic syndrome (erythroblasts>or=50%) is not specified either in the FAB or WHO classifications.
  • We retrieved the files of 74 erythroid-predominant myelodysplastic syndrome patients (17% of all myelodysplastic syndrome) and 192 myelodysplastic syndrome controls (erythroblasts<50%).
  • In erythroid-predominant myelodysplastic syndrome, by enumerating blasts from marrow nonerythroid cells rather than from total nucleated cells, 41 of 74 (55%) cases would be upgraded, either by disease subcategory or International Prognostic Scoring System.
  • We conclude that in erythroid-predominant myelodysplastic syndrome, blast calculation as a proportion of marrow nonerythroid rather than total nucleated cells can better stratify patients into prognostically relevant groups.
  • [MeSH-major] Bone Marrow Cells / pathology. Erythroblasts / pathology. Erythroid Precursor Cells / pathology. Myelodysplastic Syndromes / diagnosis

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18839018.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Alarcon F, Bonaïti-Pellié C, Harari-Kermadec H: A nonparametric method for penetrance function estimation. Genet Epidemiol; 2009 Jan;33(1):38-44
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In diseases caused by a deleterious gene mutation, knowledge of age-specific cumulative risks is necessary for medical management of mutation carriers.
  • When pedigrees are ascertained through at least one affected individual, ascertainment bias can be corrected by using a parametric method such as the Proband's phenotype Exclusion Likelihood, or PEL, that uses a survival analysis approach based on the Weibull model.
  • IDEAL is compared with PEL, using family samples simulated from a Weibull distribution and under alternative models.
  • We show that, under Weibull assumption and asymptotic conditions, IDEAL and PEL both provide unbiased risk estimates.
  • However, when the true risk function deviates from a Weibull distribution, we show that the PEL might provide biased estimates while IDEAL remains unbiased.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618769.001).
  • [ISSN] 0741-0395
  • [Journal-full-title] Genetic epidemiology
  • [ISO-abbreviation] Genet. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Won JH, Han SH, Bae SB, Kim CK, Lee NS, Lee KT, Park SK, Hong DS, Lee DW, Park HS: Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol; 2006 May;83(4):328-30
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a recently recognized disease that occurs most often in immunosuppressed patients, either with human immunodeficiency virus (HIV) or in the posttransplantation setting, and it occasionally occurs in nonimmunosuppressed patients.
  • PEL rarely responds to systemic chemotherapy, and the prognosis is poor, with a median survival time of less than 6 months for most cohorts.
  • A standard treatment for PEL has not yet been identified.
  • We describe a patient with HIV-seronegative PEL who relapsed after combination chemotherapy and then underwent successful treatment with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
  • The treatment was well tolerated, and the patient has been in remission for 12 months after HDC and ASCT.
  • [MeSH-minor] Disease-Free Survival. HIV Seropositivity. Humans. Male. Middle Aged. Prognosis. Recurrence. Transplantation, Autologous


42. Hussain AR, Khan AS, Ahmed SO, Ahmed M, Platanias LC, Al-Kuraya KS, Uddin S: Apigenin induces apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells. Cell Prolif; 2010 Apr;43(2):170-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apigenin induces apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells.
  • OBJECTIVE: The mechanisms that regulate mitogenic and antiapoptotic signals in primary effusion lymphoma (PEL) are not well known.
  • In efforts to identify novel approaches to block the proliferation of PEL cells, we assessed the effect of apigenin (4',5,7-trihydroxyflavone), a flavonoid on a panel of PEL cell lines.
  • MATERIALS AND METHODS: We studied the effect of apigenin on four PEL cell lines.
  • RESULTS: Apigenin induced apoptosis in PEL cell lines in a dose dependent manner.
  • Apigenin treatment of PEL cells caused dephosphorylation of p-Bad protein leading to down regulation of the anti-apoptotic protein, Bcl-2 and an increase in Bax/Bcl2 ratio.
  • Finally, treatment of PEL cells with apigenin down-regulated the expression of inhibitor of apoptosis protein (IAPs).
  • CONCLUSIONS: Altogether, these data suggest a novel function for apigenin, acting as a suppressor of AKT/PKB pathway in PEL cells, and raise the possibility that this agent may have a future therapeutic role in PEL and possibly other malignancies with constitutive activation of the AKT/PKB pathway.


43. Nair P, Pan H, Stallings RL, Gao SJ: Recurrent genomic imbalances in primary effusion lymphomas. Cancer Genet Cytogenet; 2006 Dec;171(2):119-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphomas (PEL) form a subset of AIDS-related lymphomas and usually have a poor prognosis.
  • Although Kaposi's sarcoma-associated herpes virus (KSHV) is often associated with PEL, very little is known about the exact mechanisms or causative effects of these associations.
  • We investigated the chromosomal imbalances in six KSHV-positive PEL cell lines using comparative genomic hybridization analysis.
  • The recurrent nature of the gains found in these chromosomal regions suggests that these imbalances play roles in the pathogenesis of PEL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Mar 1;101(5):1956-61 [12406869.001]
  • [Cites] J Infect Dis. 1999 Nov;180(5):1466-76 [10515805.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):305-19 [16075461.001]
  • [Cites] J Clin Virol. 2000 May;16(3):215-24 [10738140.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Hematol J. 2001;2(3):172-9 [11920242.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):595-601 [12002764.001]
  • [Cites] AIDS Patient Care STDS. 2004 Feb;18(2):67-73 [15006181.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] J Med Genet. 1999 Jul;36(7):511-7 [10424810.001]
  • (PMID = 17116491.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096512; United States / NCI NIH HHS / CA / R01 CA096512-02; United States / NCI NIH HHS / CA / R01 CA096512-03; United States / NCI NIH HHS / CA / R01 CA124332; United States / NCI NIH HHS / CA / CA096512-01A2; United States / NCI NIH HHS / CA / CA096512-02; United States / NCI NIH HHS / CA / R01 CA124332-01A2; United States / NCI NIH HHS / CA / R01 CA096512-01A2; United States / NCI NIH HHS / CA / R01 CA096512-04; United States / NCI NIH HHS / CA / R01 CA132637
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS165930; NLM/ PMC2799290
  •  go-up   go-down


44. Nemunaitis MC, Schussler JM, Shiller SM, Sloan LM, Mennel RG: Primary effusion lymphoma diagnosed by pericardiocentesis. Proc (Bayl Univ Med Cent); 2009 Jan;22(1):77-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL), formerly known as body cavity-based lymphoma, is a high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi's sarcoma and human herpesvirus 8 infection.
  • PEL is often diagnosed in patients with HIV infection and carries a poor prognosis, with median survival near 6 months.
  • We describe a patient who presented with symptomatic pericardial effusion, secondary to newly diagnosed PEL, and no prior history of HIV infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):447-55 [16093794.001]
  • [Cites] Ann Hematol. 2005 Aug;84(8):551-2 [15800785.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):77-82 [15662128.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3102-8 [15837766.001]
  • [Cites] Leukemia. 2005 Mar;19(3):473-6 [15674353.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Leukemia. 1999 May;13(5):664-70 [10374868.001]
  • [Cites] Am J Hematol. 1998 Mar;57(3):266 [9495391.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4894-900 [9389706.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] Clin Pharmacol Ther. 1978 Jan;23(1):68-72 [618710.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1699-704 [15343345.001]
  • [Cites] AIDS Patient Care STDS. 2004 Feb;18(2):67-73 [15006181.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):439-43 [11378560.001]
  • [Cites] JAMA. 2001 Apr 11;285(14):1880-5 [11308402.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] AIDS. 2001 Jan 26;15(2):280-2 [11216942.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):729-36 [10793109.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1792-801 [17568816.001]
  • [Cites] Oncologist. 2007 May;12(5):569-76 [17522245.001]
  • [Cites] J Cardiol. 2007 Apr;49(4):205-10 [17460882.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1849-50 [16766593.001]
  • [Cites] Int J Hematol. 2006 May;83(4):328-30 [16757433.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • (PMID = 19169406.001).
  • [ISSN] 0899-8280
  • [Journal-full-title] Proceedings (Baylor University. Medical Center)
  • [ISO-abbreviation] Proc (Bayl Univ Med Cent)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2626366
  •  go-up   go-down


45. Gasperini P, Sakakibara S, Tosato G: Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis. J Leukoc Biol; 2008 Oct;84(4):994-1000
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS)-associated herpesvirus is associated with the proliferative/malignant disorders KS, primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD) in patients with AIDS.
  • In spite of recent advances in the treatment of KS, PEL and MCD represent therapeutic challenges.
  • Recent advances in dissecting the pathogenesis of these diseases have indicated that the viral cytokine IL-6 and the cellular cytokines/growth factors IL-10, IL-6, stromal cell-derived factor 1, and vascular endothelial growth factor are important contributors to the growth, survival, and spread of PEL and MCD and are therefore potential targets for drug development.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Animals. Antiretroviral Therapy, Highly Active. Cell Division. Cell Survival. Disease Models, Animal. Humans. Interleukin-10 / immunology. Interleukin-6 / immunology. Mice. Mice, Inbred NOD. Mice, SCID. Vascular Endothelial Growth Factor A / immunology

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 May 1;67(9):4042-51 [17483315.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Transplantation. 2007 Jul 15;84(1):40-5 [17627235.001]
  • [Cites] J Clin Invest. 1999 Nov;104(9):1199-211 [10545519.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1109-10 [10691336.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4672-7 [10779772.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33189-92 [10961983.001]
  • [Cites] J Exp Med. 2000 Aug 21;192(4):495-506 [10952719.001]
  • [Cites] Eur J Immunol. 2001 Feb;31(2):350-9 [11180098.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Science. 2001 Mar 16;291(5511):2150-5 [11251120.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2526-7 [11307774.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):965-9 [11581297.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3042-9 [11698289.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3473-5 [11719390.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Science. 2003 Jun 27;300(5628):2101-4 [12829785.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3900-5 [12907452.001]
  • [Cites] Science. 1988 Jan 29;239(4839):502-4 [2829354.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] Physiol Rev. 1991 Jan;71(1):93-127 [1986393.001]
  • [Cites] J Exp Med. 1991 Nov 1;174(5):1275-8 [1940805.001]
  • [Cites] Semin Oncol. 1993 Dec;20(6):636-47 [8296200.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1243-54 [7632928.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Biol Chem. 1996 Jan 12;271(2):736-41 [8557680.001]
  • [Cites] AIDS. 1996 Jan;10(1):61-7 [8924253.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1198-201 [9129085.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4894-900 [9389706.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2475-81 [9516148.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] Immunity. 1999 Jan;10(1):39-49 [10023769.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51793-803 [15258150.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] Acta Oncol. 2004;43(8):698-704 [15764213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5 [15781862.001]
  • [Cites] J Med Chem. 2005 Oct 20;48(21):6661-70 [16220982.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):140-58 [16828973.001]
  • [Cites] J Virol. 2006 Oct;80(19):9811-21 [16973585.001]
  • [Cites] J Virol. 2006 Nov;80(21):10874-8 [16956953.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • (PMID = 18319288.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; 130068-27-8 / Interleukin-10
  • [Number-of-references] 57
  • [Other-IDs] NLM/ PMC2538598
  •  go-up   go-down


46. Sarek G, Järviluoma A, Moore HM, Tojkander S, Vartia S, Biberfeld P, Laiho M, Ojala PM: Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS Pathog; 2010 Mar;6(3):e1000818
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncogenic Kaposi's sarcoma herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma, primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD).
  • In the infected host cell KSHV displays two modes of infection, the latency and productive viral replication phases, involving extensive viral DNA replication and gene expression.
  • Our study demonstrates that the KSHV v-cyclin and cellular CDK6 kinase phosphorylate NPM on threonine 199 (Thr199) in de novo and naturally KSHV-infected cells and that NPM is phosphorylated to the same site in primary KS tumors.
  • Strikingly, depletion of NPM in PEL cells leads to viral reactivation, and production of new infectious virus particles.
  • Moreover, the phosphorylation of NPM negatively correlates with the level of spontaneous viral reactivation in PEL cells.


47. Lancaster LS, Bowker RM, Mauer WA: Density and morphologic features of primary epidermal laminae in the feet of three-year-old racing Quarter Horses. Am J Vet Res; 2007 Jan;68(1):11-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Density and morphologic features of primary epidermal laminae in the feet of three-year-old racing Quarter Horses.
  • OBJECTIVE: To quantify the density of primary epidermal laminae (PELs) around the solar circumference and evaluate the relationship between regional PEL density and hoof capsule morphology in horses.
  • PROCEDURES: Data pertaining to gross features of hoof morphology and PEL variables, including number, density, and distribution patterns around the perimeter of the hoof wall and number of bar PELs, were collected.
  • RESULTS: No significant differences were found between left and right forefeet with respect to gross hoof morphologic measurements.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Variations were detected in PEL density and morphology around the solar circumference of hooves from 3-year-old racing Quarter Horses.
  • A better understanding of relationships between laminar density, laminar morphology, and gross morphology of the hoof capsule in different populations of horses may aid practitioners in diagnosis and treatment of disease involving the hoof wall in horses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17199413.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Payasi A, Misra PC, Sanwal GG: Purification and characterization of pectate lyase from banana (Musa acuminata) fruits. Phytochemistry; 2006 May;67(9):861-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification and characterization of pectate lyase from banana (Musa acuminata) fruits.
  • Pectate lyase (PEL) has been purified by hydrophobic, cation exchange and size exclusion column chromatographies from ripe banana fruit.
  • PEL is sensitive to inhibition by different phenolic compounds, thiols, reducing agents, iodoacetate and N-bromosuccinimide.
  • The banana PEL is a enzyme requiring Mg(2+), in addition to Ca(2+), for exhibiting maximum activity.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554075.001).
  • [ISSN] 0031-9422
  • [Journal-full-title] Phytochemistry
  • [ISO-abbreviation] Phytochemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


49. Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B: Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood; 2010 Jun 3;115(22):4455-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) constitutes a subset of non-Hodgkin lymphoma whose incidence is highly increased in the context of HIV infection.
  • Kaposi sarcoma-associated herpesvirus is the causative agent of PEL.
  • The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays a critical role in cell proliferation and survival, and this pathway is dysregulated in many different cancers, including PEL, which display activated PI3K, Akt, and mammalian target of rapamycin (mTOR) kinases.
  • We compared different compounds that inhibit the PI3K/Akt/mTOR pathway in PEL.
  • Although compounds that modulated activity of only a single pathway member inhibited PEL proliferation, the use of a novel compound, NVP-BEZ235, that dually inhibits both PI3K and mTOR kinases was significantly more efficacious in culture and in a PEL xenograft tumor model.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):627-32 [10627472.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3102-11 [17656647.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2641-8 [11289142.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):1001-13 [11581301.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25226-32 [11994296.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):923-32 [12370270.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1281-7 [12379847.001]
  • [Cites] Anticancer Drugs. 2003 Feb;14(2):167-73 [12569304.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):131-43 [12620408.001]
  • [Cites] Cell. 2003 Nov 26;115(5):577-90 [14651849.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] J Virol. 2004 Feb;78(4):1918-27 [14747556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6 [15047889.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2774-81 [15087393.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2635-43 [9108380.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Science. 1997 Oct 24;278(5338):687-9 [9381178.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1122-8 [15467718.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] J Pathol. 2005 May;206(1):68-75 [15751051.001]
  • [Cites] Mol Cell. 2005 Apr 15;18(2):143-5 [15837416.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] Blood. 2006 Jan 15;107(2):760-8 [16189274.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):3979-87 [18056705.001]
  • [Cites] Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50 [18166498.001]
  • [Cites] J Virol. 2008 Jul;82(13):6514-23 [18434405.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4640-8 [18559509.001]
  • [Cites] Oncogene. 2008 Jun 26;27(28):3999-4007 [18278068.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):1851-63 [18606717.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8022-30 [18829560.001]
  • [Cites] Haematologica. 2009 Aug;94(8):1170-4 [19608668.001]
  • [Cites] Curr Opin Cell Biol. 2009 Apr;21(2):154-65 [19230644.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):430-7 [16505118.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3658-66 [16585191.001]
  • [Cites] Blood. 2006 May 15;107(10):4053-62 [16418332.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Cell. 2006 Sep 8;126(5):955-68 [16959574.001]
  • [Cites] J Virol. 2007 Feb;81(4):1912-22 [17121789.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Cancer Cell. 2007 May;11(5):395-406 [17482130.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Leukemia. 2000 Feb;14(2):285-91 [10673746.001]
  • (PMID = 20299510.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA163217; United States / NIAID NIH HHS / AI / P30-AI045008; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA096500; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIAID NIH HHS / AI / P30 AI045008; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / T32 CA071341; United States / NCI NIH HHS / CA / CA121947; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / U01 CA121947; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / T32CA071341; United States / NCI NIH HHS / CA / R01 CA096500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Imidazoles; 0 / Intracellular Signaling Peptides and Proteins; 0 / Protein Kinase Inhibitors; 0 / Quinolines; 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; 107-73-3 / Phosphorylcholine; 2GWV496552 / perifosine; 53EY29W7EC / miltefosine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; RUJ6Z9Y0DT / dactolisib
  • [Other-IDs] NLM/ PMC2881502
  •  go-up   go-down


50. Adiguzel C, Bozkurt SU, Kaygusuz I, Uzay A, Tecimer T, Bayik M: Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature. APMIS; 2009 Mar;117(3):222-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature.
  • Primary effusion lymphoma (PEL) is a very rare type of lymphoma usually confined to the body cavities predominantly in immunosuppressed patients infected with human herpes virus 8 (HHV-8).
  • The new term for HHV-8 independent PEL is HHV8-unrelated PEL-like lymphoma.
  • We describe an 89-year-old human immunodeficiency virus (HIV)-negative male patient with HHV8-unrelated PEL-like lymphoma in the pleura.
  • One year after the diagnosis, a new pleural effusion developed at the left side.
  • Following thoracentesis and pleurodesis, the patient remained in complete remission for 40 months.
  • To date, 30 cases of HHV8-unrelated PEL-like lymphoma/HIV negative have been reported in the literature.
  • The outcome of the HHV8-unrelated PEL-like lymphoma patients who were HIV negative seems to be better than HIV- and HHV-8-positive PEL.
  • [MeSH-major] Lymphoma, Primary Effusion / diagnosis. Neoplasm Regression, Spontaneous. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Herpesvirus 8, Human. Humans. Male. Paracentesis. Pleurodesis. Prognosis. Remission Induction. Tomography Scanners, X-Ray Computed

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19245595.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 31
  •  go-up   go-down


51. Sepulchre JA, Reverchon S, Nasser W: Modeling the onset of virulence in a pectinolytic bacterium. J Theor Biol; 2007 Jan 21;244(2):239-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Building up from experimental knowledge of the regulatory network of the pel genes in the bacteria E. chrysanthemi, we propose for the first time a qualitative modeling of the infectious transition of this bacteria when it is hosted in a plant.
  • We show that this infectious transition can be understood as the excitable dynamics of a metabolico-genetic network.
  • The latent stage is characterized by a moderate but unequivocal expression of the virulence gene, waiting for a number of conditions which have to fulfill in order to trigger a fully developed infection.
  • In the virulent state the bacteria synthesize a massive production of virulence factors including pectate lyases (Pel) which favor the invasion of the host plant tissues.
  • Moreover it can be interpreted with respect to the relatively complex structure of the binding sites of pel.
  • From the biological point of view, our simulations validate the picture that the promoter of pel has evolved to form a security device preventing a hastened expression of these virulent genes.
  • This first modeling of the regulation of pel genes opens the way to new confrontations between theoretical ideas with experiments and possible strategies to fight the soft-rot disease of plants.
  • [MeSH-minor] Gene Expression Regulation, Bacterial. Genes, Bacterial. Polysaccharide-Lyases / biosynthesis. Polysaccharide-Lyases / genetics. Promoter Regions, Genetic. Virulence / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005207.001).
  • [ISSN] 0022-5193
  • [Journal-full-title] Journal of theoretical biology
  • [ISO-abbreviation] J. Theor. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


52. O'Hara AJ, Vahrson W, Dittmer DP: Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood; 2008 Feb 15;111(4):2347-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma.
  • MicroRNAs are regulated by gene alteration, transcription, and processing.
  • Thus far, few studies have simultaneously assessed all 3 levels of regulation.
  • Using real-time quantitative polymerase chain reaction (QPCR)-based arrays, we determined changes in gene copy number, pre-miRNA, and mature miRNA levels for the largest set of primary effusion lymphomas (PELs) to date.
  • We detected PEL-specific miRNA gene amplifications, and concordant changes in pre-miRNA and mature miRNA.
  • We identified 68 PEL-specific miRNAs.
  • This defines the miRNA signature of PEL and shows that transcriptional regulation of pre-miRNA as well as mature miRNA levels contribute nonredundant information that can be used for the classification of human tumors.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1454-61 [12424116.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84 [12902540.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):415-9 [14508493.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1511-8 [15070997.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] Mol Cell. 2004 Jul 23;15(2):185-97 [15260970.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):343-9 [15372041.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] Nucleic Acids Res. 2005;33(8):2697-706 [15891114.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Nucleic Acids Res. 2005;33(17):5394-403 [16192569.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):e182 [16314296.001]
  • [Cites] J Virol. 2006 Jun;80(11):5321-6 [16699012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3068-71 [16849646.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Dec;171(2):119-21 [17116491.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Nature. 2000 Mar 16;404(6775):293-6 [10749213.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]
  • [Cites] Cell. 2001 Jul 13;106(1):23-34 [11461699.001]
  • [Cites] J Infect Dis. 2007 Mar 1;195(5):645-59 [17262705.001]
  • [Cites] Oncogene. 2007 May 31;26(26):3769-76 [17173072.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5017-22 [17297439.001]
  • [Cites] Nat Biotechnol. 2007 Sep;25(9):996-7 [17846629.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • (PMID = 18079361.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA121947; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / U01 CA121947; United States / NIDCR NIH HHS / DE / DE018304-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2234063
  •  go-up   go-down


53. Price CT, Jones SC, Amundson KE, Kwaik YA: Host-mediated post-translational prenylation of novel dot/icm-translocated effectors of legionella pneumophila. Front Microbiol; 2010;1:131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Dot/Icm type IV translocated Ankyrin B (AnkB) effector of Legionella pneumophila is modified by the host prenylation machinery that anchors it into the outer leaflet of the Legionella-containing vacuole (LCV), which is essential for biological function of the effector in vitro and in vivo.
  • In silico analyses of four sequenced L. pneumophila genomes revealed the presence of eleven other genes that encode proteins with a C-terminal eukaryotic CaaX prenylation motif.
  • Of these eleven designated Prenylated effectors of Legionella (Pel), seven are also found in L. pneumophila AA100.
  • We show that six L. pneumophila AA100 Pel proteins exhibit distinct cellular localization when ectopically expressed in mammalian cells and this is dependent on action of the host prenylation machinery and the conserved cysteine residue of the CaaX motif.
  • Five of the Pel proteins are injected into human macrophages by the Dot/Icm type IV translocation system of L. pneumophila.
  • Taken together, the Pel proteins are novel Dot/Icm-translocated effectors of L. pneumophila that are post-translationally modified by the host prenylation machinery, which enables their anchoring into cellular membranes, and the prenylated effectors contribute to evasion of lysosomal fusion by the LCV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Immun. 2010 May;78(5):2079-88 [20194593.001]
  • [Cites] PLoS Pathog. 2009 Dec;5(12):e1000704 [20041211.001]
  • [Cites] Mol Cancer Ther. 2010 May;9(5):1111-9 [20406948.001]
  • [Cites] J Exp Med. 2010 Aug 2;207(8):1713-26 [20660614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5868-72 [2116010.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5873-7 [2116011.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1167-77 [2661017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(21):8323-7 [2682646.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):26802-6 [7592920.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14459-64 [9162087.001]
  • [Cites] Science. 1998 Feb 6;279(5352):873-6 [9452389.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1669-74 [9465074.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):6221-6 [7890759.001]
  • [Cites] Mol Microbiol. 1994 Nov;14(3):583-94 [7885236.001]
  • [Cites] Nat Cell Biol. 2002 Dec;4(12):945-54 [12447391.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14196-202 [12574170.001]
  • [Cites] Appl Environ Microbiol. 2005 Jan;71(1):20-8 [15640165.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14620-7 [15710609.001]
  • [Cites] Mol Biol Cell. 1992 Mar;3(3):275-86 [1627830.001]
  • [Cites] J Lipid Res. 2006 May;47(5):883-91 [16543601.001]
  • [Cites] PLoS Pathog. 2006 Apr;2(4):e34 [16652170.001]
  • [Cites] Environ Microbiol. 2008 Jun;10(6):1460-74 [18279343.001]
  • [Cites] Cell Microbiol. 2008 Jun;10(6):1209-20 [18363881.001]
  • [Cites] PLoS Pathog. 2008;4(8):e1000117 [18670632.001]
  • [Cites] Mol Microbiol. 2008 Nov;70(4):908-23 [18811729.001]
  • [Cites] Nat Rev Microbiol. 2009 Jan;7(1):13-24 [19011659.001]
  • [Cites] Cell Host Microbe. 2009 Jun 18;5(6):571-9 [19527884.001]
  • [Cites] Cell Microbiol. 2009 Oct;11(10):1435-43 [19563462.001]
  • [Cites] Nat Rev Microbiol. 2009 Sep;7(9):654-65 [19680249.001]
  • [Cites] Cell Microbiol. 2009 Nov;11(11):1579-86 [19775254.001]
  • [Cites] Trends Microbiol. 2010 Mar;18(3):132-9 [19962898.001]
  • [Cites] Cell Microbiol. 2010 Sep 1;12(9):1272-91 [20345489.001]
  • (PMID = 21687755.001).
  • [ISSN] 1664-302X
  • [Journal-full-title] Frontiers in microbiology
  • [ISO-abbreviation] Front Microbiol
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI043965; United States / NIAID NIH HHS / AI / R01 AI069321
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3109360
  • [Keywords] NOTNLM ; Agrobacterium / AnkB / CaaX / Dot/Icm / F-box / IcmT / Legionnaires’ / PFT / PGGT / Pel / RCE-1 / ankyrin / prenylation
  •  go-up   go-down


54. Bian C, Yuan C, Lin L, Lin J, Shi X, Ye X, Huang Z, Huang M: Purification and preliminary crystallographic analysis of a Penicillium expansum lipase. Biochim Biophys Acta; 2005 Aug 31;1752(1):99-102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification and preliminary crystallographic analysis of a Penicillium expansum lipase.
  • PF898 is a strain of Penicillium expansum optimized for the high level production of Penicillium expansum lipase (PEL).
  • This PEL is unique compared with other lipases in several aspects, For example, the PEL shows low sequence identities (<30%) to all other known lipases, and high percentage of hydrophobic residues in the N-terminal region.
  • The PEL was purified to homogeneity and shown to be 28 kDa by SDS-PAGE.
  • The crystals have tetragonal lattice and unit-cell parameters of a=b=88.09 A, c=126.54 A.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112629.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.1.1.3 / Lipase
  •  go-up   go-down


55. Simonelli C, Tedeschi R, Gloghini A, Bortolin MT, Spina M, Bidoli E, Cinelli R, De Paoli P, Carbone A, Tirelli U: Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis; 2005 Apr 1;40(7):1022-7
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary effusion lymphoma (PEL) represents a peculiar lymphoma infected with human herpesvirus 8 (HHV-8) and occurs predominantly in human immunodeficiency virus (HIV)-infected patients.
  • The aim of the present study was to evaluate the immunologic and virological parameters, including HHV-8 viremia, of 5 HIV-infected patients with PEL whose disease was diagnosed and treated at our institute.
  • Biological parameters, such as latent and lytic HHV-8 antigen levels, plasma HHV-8 load, Epstein-Barr virus plasma DNA load, HIV-1 load, and CD4 cell count, were assessed before treatment, during therapy, and at follow-up.
  • RESULTS: Four patients were treated with chemotherapy and highly active antiretroviral therapy (HAART), and 1 was treated with HAART alone; 3 of 5 patients reached complete remission.
  • HHV-8 levels decreased after therapy in 4 patients.
  • CONCLUSIONS: Our analysis demonstrates that HHV-8 can be detected in the plasma at the onset of PEL; its prognostic role needs to be explored.
  • CD4 cell count seems to be the most important indicator of progression of PEL.
  • [MeSH-minor] Adult. Anti-HIV Agents. CD4 Lymphocyte Count. Disease Progression. Female. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Humans. Male. Viral Load. Viral Proteins / metabolism. Viremia

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824995.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Viral Proteins
  •  go-up   go-down


56. Siddiqi T, Joyce RM: A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma; 2008 Oct;8(5):300-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare B-cell non-Hodgkin lymphoma that usually occurs in HIV-positive patients and has a very poor prognosis with limited treatment options.
  • Prospective studies are lacking to define the standard of care for this disease, and various case series report median survival at 6 months with anthracycline-based chemotherapy.
  • Herein, we report a case of an elderly HIV-negative man of Mediterranean origin who was diagnosed with primary effusion lymphoma and responded dramatically to 6 cycles of a combination of bortezomib, pegylated liposomal doxorubicin, and rituximab.
  • He has since been maintained on rituximab and remains in complete remission 2 years after diagnosis.
  • In this report, we discuss the rationale for using these agents in this patient and advocate the further study of bortezomib-based therapy in PEL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Primary Effusion / diagnosis


57. Mancuso JD, McCoy J, Pelka B, Kahn PJ, Gaydos JC: The challenge of controlling lead and silica exposures from firing ranges in a special operations force. Mil Med; 2008 Feb;173(2):182-6
Hazardous Substances Data Bank. Lead, elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2000, soldiers from a Special Operations Force had airborne lead exposures 20 to 38 times the permissible exposure limit.
  • Their average blood lead level was 13.9 microg/dL.
  • In 2003, investigators learned that the unit also used an outdoor firing range with exposures exceeding the permissible exposure limit.
  • The average blood lead level in the unit was 6.8 microg/dL in 2005, a reduction of 51%.
  • [MeSH-major] Air Pollutants, Occupational / analysis. Firearms. Lead / analysis. Occupational Exposure / prevention & control. Silicon Dioxide / analysis

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333495.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 2P299V784P / Lead; 7631-86-9 / Silicon Dioxide
  •  go-up   go-down


58. Wong SS, Vargas J, Thomas A, Fastje C, McLaughlin M, Camponovo R, Lantz RC, Heys J, Witten ML: In vivo comparison of epithelial responses for S-8 versus JP-8 jet fuels below permissible exposure limit. Toxicology; 2008 Dec 5;254(1-2):106-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo comparison of epithelial responses for S-8 versus JP-8 jet fuels below permissible exposure limit.
  • This study was designed to characterize and compare the pulmonary effects in distal lung from a low-level exposure to jet propellant-8 fuel (JP-8) and a new synthetic-8 fuel (S-8).
  • A pulmonary function test performed 24h after the final exposure indicated that there was a significant increase in expiratory lung resistance in the S-8 mice, whereas JP-8 mice had significant increases in both inspiratory and expiratory lung resistance compared to control values.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Electrophoresis. 1999 Dec;20(18):3659-69 [10612293.001]
  • [Cites] Toxicology. 2004 Apr 15;197(2):139-47 [15003324.001]
  • [Cites] Toxicol Sci. 2000 Dec;58(2):290-8 [11099641.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 May;282(5):L1075-81 [11943673.001]
  • [Cites] Toxicol Ind Health. 2001 Feb;17(1):23-9 [12004922.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Aug;27(2):170-8 [12151308.001]
  • [Cites] Toxicol Sci. 2003 Dec;76(2):347-56 [14514957.001]
  • [Cites] J Med Dent Sci. 2003 Sep;50(3):195-202 [15074357.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):301-8 [15093277.001]
  • [Cites] J Toxicol Environ Health A. 2004 Jul 23;67(14):1109-29 [15205027.001]
  • [Cites] Acta Psychiatr Scand. 1979 Jul;60(1):39-49 [474176.001]
  • [Cites] Acta Psychiatr Scand Suppl. 1983;303:55-67 [6575584.001]
  • [Cites] Toxicol Appl Pharmacol. 1984 Aug;75(1):44-51 [6464021.001]
  • [Cites] Scand J Work Environ Health. 1985 Dec;11(6):433-7 [4095521.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):454-64 [3717299.001]
  • [Cites] Toxicol Ind Health. 1995 May-Jun;11(3):325-36 [7482572.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 Jul;15(1):1-8 [8679213.001]
  • [Cites] J Appl Toxicol. 1996 May-Jun;16(3):197-200 [8818858.001]
  • [Cites] Toxicol Ind Health. 1997 Jan-Feb;13(1):43-55 [9098949.001]
  • [Cites] J Occup Environ Med. 1997 Jul;39(7):623-32 [9253723.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):L229-38 [9950884.001]
  • [Cites] Drug Chem Toxicol. 1999 Feb;22(1):155-64 [10189576.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jul;21(1):44-53 [10385592.001]
  • [Cites] Toxicol Sci. 1999 Sep;51(1):119-25 [10496683.001]
  • [Cites] Phys Med Biol. 2005 Apr 7;50(7):1405-19 [15798332.001]
  • [Cites] J Chromatogr A. 2005 Nov 4;1093(1-2):11-20 [16233866.001]
  • [Cites] Environ Health Perspect. 2006 Feb;114(2):182-5 [16451852.001]
  • [Cites] J Toxicol Sci. 2006 Aug;31(3):219-28 [16960432.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Oct;35(4):479-87 [16690985.001]
  • [Cites] Int J Toxicol. 2007 Jul-Aug;26(4):325-9 [17661223.001]
  • [Cites] J Appl Toxicol. 2008 May;28(4):543-53 [17966119.001]
  • [Cites] Toxicol Pathol. 2000 Sep-Oct;28(5):656-63 [11026600.001]
  • (PMID = 18930109.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES006694-14; United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NIEHS NIH HHS / ES / ES06694; United States / NIEHS NIH HHS / ES / P30 ES006694-14
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Hydrocarbons; 0 / JP8 aviation fuel; 0 / S-8 fuel
  • [Other-IDs] NLM/ NIHMS208577; NLM/ PMC2927360
  •  go-up   go-down


59. Deeraksa A, Moonmangmee S, Toyama H, Yamada M, Adachi O, Matsushita K: Characterization and spontaneous mutation of a novel gene, polE, involved in pellicle formation in Acetobacter tropicalis SKU1100. Microbiology; 2005 Dec;151(Pt 12):4111-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization and spontaneous mutation of a novel gene, polE, involved in pellicle formation in Acetobacter tropicalis SKU1100.
  • In this study, a gene required for pellicle formation by the R strain was investigated by transposon mutagenesis using Tn10.
  • The resulting mutant, designated Pel-, has a smooth-surfaced colony and a defect in pellicle formation, as for the S strain.
  • An ORF was identified at the Tn10 insertion site, designated polE, upstream of which polABCD genes were also found.
  • The deduced amino acid sequences of polABCD showed a high level of homology to those of rfbBACD which are involved in dTDP-rhamnose synthesis, whereas polE had a relatively low level of homology to glycosyltransferase.
  • A plasmid harbouring the polE or polB genes could restore pellicle formation in the Pel(-) mutant and S strains, and in the DeltapolB mutant, respectively.
  • The Pel- and DeltapolB mutants were unable to grow in static culture and became more sensitive to acetic acid due to the loss of pellicle formation.
  • Additionally, this study identified the mutation sites of several S strains which were spontaneously isolated from the original culture and found them to be concentrated in a sequence of 7 C residues in the coding sequence of polE, with the deletion or addition of a single C nucleotide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16339956.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB195173
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Monosaccharides; 0 / Polysaccharides, Bacterial
  •  go-up   go-down


60. Liu A, Lang Y, Xue L, Liu J: Ecological risk analysis of polycyclic aromatic hydrocarbons (PAHs) in surface sediments from Laizhou Bay. Environ Monit Assess; 2009 Dec;159(1-4):429-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The total PAHs concentrations were at lower level compared to other marine coastal areas.
  • It was showed that concentrations of PAHs were below their respective effects range-median (ERM) and probable effects level (PEL) values in 17 stations using effects range-low (ERL)/ERM values and threshold effects level (TEL)/PEL values.
  • Acenaphthene concentrations in surface sediment exceed TEL only in station L14, the concentrations were at levels where adverse biological effects may occasionally occur (> or =TEL and <PEL) in the station.
  • Fluorene concentrations were in the intermediate range (> or =ERL/TEL and <ERM/PEL) in stations L05, L07, L15, and L16, indicating that occasionally adverse biological effects were likely to occur for fluorene at the four stations.
  • Acenaphthylene levels in all stations are lower than corresponding ERL values, while TEL level was exceeded in 59% of the stations.
  • Naphthalene concentrations exceeded ERL only in station L05, while naphthalene levels in 59% of the stations were in the intermediate range (> or =TEL and <PEL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mar Pollut Bull. 2005 Mar;50(3):319-26 [15757695.001]
  • [Cites] Environ Monit Assess. 2007 Feb;125(1-3):229-37 [17219246.001]
  • [Cites] Mar Pollut Bull. 2004 May;48(9-10):946-53 [15111042.001]
  • [Cites] Environ Sci Technol. 2005 Mar 15;39(6):1861-7 [15819248.001]
  • [Cites] Sci Total Environ. 2007 Mar 1;374(1):112-26 [17258286.001]
  • [Cites] Mar Pollut Bull. 2003 May;46(5):619-25 [12735959.001]
  • [Cites] Environ Int. 2006 May;32(4):455-65 [16337000.001]
  • [Cites] Environ Monit Assess. 2007 Oct;133(1-3):447-58 [17268918.001]
  • [Cites] Environ Int. 2006 Apr;32(3):388-96 [16289759.001]
  • [Cites] Ecotoxicology. 1996 Aug;5(4):253-78 [24193815.001]
  • [Cites] Mar Pollut Bull. 2007;55(10-12):451-8 [17936311.001]
  • [Cites] Environ Monit Assess. 2006 Sep;120(1-3):187-220 [16773229.001]
  • (PMID = 19058021.001).
  • [ISSN] 1573-2959
  • [Journal-full-title] Environmental monitoring and assessment
  • [ISO-abbreviation] Environ Monit Assess
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Polycyclic Aromatic Hydrocarbons; 0 / Water Pollutants, Chemical
  •  go-up   go-down


61. Occupational Safety and Health Administration (OSHA), Department of Labor: Occupational exposure to hexavalent chromium. Final rule. Fed Regist; 2006 Feb 28;71(39):10099-385
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to hexavalent chromium. Final rule.
  • The Occupational Safety and Health Administration (OSHA) is amending the existing standard which limits occupational exposure to hexavalent chromium (Cr(VI)).
  • OSHA has determined based upon the best evidence currently available that at the current permissible exposure limit (PEL) for Cr(VI), workers face a significant risk to material impairment of their health.
  • The record also indicates that occupational exposure to Cr(VI) may result in asthma, and damage to the nasal epithelia and skin.
  • The final rule establishes an 8-hour time-weighted average (TWA) exposure limit of 5 micrograms of Cr(VI) per cubic meter of air (5 [mu]g/cu m).
  • This is a considerable reduction from the previous PEL of 1 milligram per 10 cubic meters of air (1 mg/10 cu m, or 100 [mu]g/cu m) reported as CrO3, which is equivalent to a limit of 52 [mu]g/cu m as Cr(VI).
  • The final rule also contains ancillary provisions for worker protection such as requirements for exposure determination, preferred exposure control methods, including a compliance alternative for a small sector for which the new PEL is infeasible, respiratory protection, protective clothing and equipment, hygiene areas and practices, medical surveillance, recordkeeping, and start-up dates that include four years for the implementation of engineering controls to meet the PEL.
  • The PEL established by this rule reduces the significant risk posed to workers by occupational exposure to Cr(VI) to the maximum extent that is technologically and economically feasible.
  • [MeSH-major] Air Pollutants, Occupational / standards. Chromium / standards. Occupational Exposure / legislation & jurisprudence. Occupational Health / legislation & jurisprudence. Respiratory Tract Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528853.001).
  • [ISSN] 0097-6326
  • [Journal-full-title] Federal register
  • [ISO-abbreviation] Fed Regist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0R0008Q3JB / Chromium
  •  go-up   go-down


62. Liu J, Martin HJ, Liao G, Hayward SD: The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol; 2007 Oct;81(19):10451-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sequencing of c-Myc coding sequences revealed that c-Myc in KSHV-positive primary effusion lymphoma (PEL) cell lines is wild type in the N-terminal region that regulates c-Myc protein stability.
  • Despite this, c-Myc in PEL cells is stabilized.
  • We now show that LANA increases the level of phosphorylated extracellular signal-regulated kinase 1 (ERK1) and increases ERK phosphorylation of c-Myc on Ser62.
  • LANA-mediated manipulation of c-Myc function is likely to contribute to KSHV-associated tumorigenesis through the induction of c-Myc regulated cellular genes, as well as by the stimulation of cell cycle progression.


63. Zhang H, Yang XY, Hong T, Feldman T, Bhattacharyya PK: Kaposi sarcoma-associated herpesvirus (human herpesvirus type 8)-associated extracavitary lymphoma: Report of a case in an HIV-positive patient with simultaneous kaposi sarcoma and a review of the literature. Acta Haematol; 2010;123(4):237-41
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi sarcoma-associated herpesvirus (human herpesvirus type 8)-associated extracavitary lymphoma: Report of a case in an HIV-positive patient with simultaneous kaposi sarcoma and a review of the literature.
  • BACKGROUND: Kaposi sarcoma-associated herpesvirus (KSHV), or human herpesvirus type 8 (HHV8), is consistently identified in 2 human immunodeficiency virus (HIV)-associated lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease.
  • These solid variants of PEL are similar morphologically, immunophenotypically, clinically and genetically to classic PEL.
  • CASE REPORT: Here we report a case of a 46-year-old HIV-positive patient with lymphadenopathy and Kaposi sarcoma of the skin.
  • The lymph node biopsy shows a KSHV/HHV8-positive high-grade B-cell lymphoma with co-infection with Epstein-Barr virus, which supports the diagnosis of a solid variant of PEL.
  • CONCLUSION: Analysis of viral infection is of primary importance to define this solid variant of PEL.
  • It is believed that it is related to a few latent viral gene products including ORF73, ORF72, and ORF71 which increase proliferation and impair apoptosis through variant regulatory processes.
  • To the best of our knowledge, this is the first reported case of solid tissue PEL along with Kaposi sarcoma involving the same anatomic site.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 S. Karger AG, Basel.
  • (PMID = 20484888.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Viral Proteins
  • [Number-of-references] 22
  •  go-up   go-down


64. Sarek G, Ojala PM: p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle; 2007 Sep 15;6(18):2205-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV infection is the causative agent in three different tumor types: Kaposi's sarcoma, a plasmablastic variant of multicentric Castelman's disease and an AIDS-related form of B cell lymphoproliferative disorder called primary effusion lymphoma (PEL).
  • PEL manifests as an effusion malignancy in Kaposi's sarcoma patients with advanced AIDS, but also occurs in HIV-negative individuals.
  • PEL is a very aggressive disease, and currently there are no efficient therapies for treating PEL.
  • In our recent paper we report that p53 reactivation by a small molecule inhibitor of p53-MDM2 interaction, Nutlin-3a, induces selective and massive apoptosis in PEL cells, and has striking anti-tumor activity in a mouse xenograft PEL model.
  • In the light of current treatment regimens for PEL, we discuss here the benefits of using reactivation of the p53 pathway as a novel principle for the treatment of this virally induced highly aggressive malignancy.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890905.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 66
  •  go-up   go-down


65. Dalton-Griffin L, Wilson SJ, Kellam P: X-box binding protein 1 contributes to induction of the Kaposi's sarcoma-associated herpesvirus lytic cycle under hypoxic conditions. J Virol; 2009 Jul;83(14):7202-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV is required for development of Kaposi's sarcoma, a tumor of endothelial origin, and is associated with the B-cell tumor primary effusion lymphoma (PEL) and the plasmablastic variant of multicentric Castleman's disease, all of which are characterized by predominantly latent KSHV infection.
  • Recently, we and others have shown that the activated form of transcription factor X-box binding protein 1 (XBP-1) is a physiological trigger of KSHV lytic reactivation in PEL.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92 [9653127.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Clin Microbiol. 1999 Apr;37(4):1150-3 [10074540.001]
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):32631-7 [10551817.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] Blood. 2001 May 15;97(10):3244-50 [11342455.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3537-40 [11574569.001]
  • [Cites] J Immunol. 2001 Dec 1;167(11):6140-9 [11714773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2170-4 [11854513.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Annu Rev Biochem. 2005;74:739-89 [15952902.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5675-86 [15964822.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):39762-71 [16188879.001]
  • [Cites] Mol Cancer Res. 2005 Nov;3(11):597-605 [16317085.001]
  • [Cites] Mol Cancer Res. 2006 Jul;4(7):423-36 [16849518.001]
  • [Cites] J Virol. 2006 Aug;80(16):7965-75 [16873253.001]
  • [Cites] Circ Res. 2006 Aug 4;99(3):275-82 [16794188.001]
  • [Cites] J Clin Virol. 2006 Oct;37(2):98-103 [16931136.001]
  • [Cites] J Virol. 2006 Nov;80(21):10802-12 [16956952.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9870-7 [17047048.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] J Virol. 2007 Jul;81(14):7363-70 [17494074.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):53-66 [17612490.001]
  • [Cites] FEBS Lett. 2007 Jul 24;581(18):3485-8 [17617410.001]
  • [Cites] J Virol. 2007 Oct;81(19):10413-23 [17634230.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8605-14 [17875700.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jan 4;365(1):143-8 [17976372.001]
  • [Cites] J Virol. 2007 Dec;81(24):13566-77 [17898050.001]
  • [Cites] J Virol. 2007 Dec;81(24):13578-86 [17928342.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Virus Res. 2008 Mar;132(1-2):257-62 [18221814.001]
  • [Cites] J Virol. 2008 May;82(10):4793-806 [18337571.001]
  • [Cites] J Am Acad Dermatol. 2008 Aug;59(2):179-206; quiz 207-8 [18638627.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5943-7 [15342372.001]
  • [Cites] J Chem Neuroanat. 2004 Sep;28(1-2):79-92 [15363493.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] J Exp Med. 1996 Feb 1;183(2):393-401 [8627152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):17771-8 [8663540.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):32529-37 [8955077.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):94-102 [9207354.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19253-60 [9235919.001]
  • [Cites] J Biol Chem. 1997 Sep 5;272(36):22642-7 [9278421.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5328-35 [9393757.001]
  • [Cites] Lancet Infect Dis. 2002 May;2(5):281-92 [12062994.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11920-5 [12154231.001]
  • [Cites] J Virol. 2003 Jun;77(12):6761-8 [12767996.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • (PMID = 19403667.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Immediate-Early Proteins; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Transcription Factors; 0 / regulatory factor X transcription factors
  • [Other-IDs] NLM/ PMC2704782
  •  go-up   go-down


66. Hsieh PY, Huang SI, Li DK, Mao TL, Sheu JC, Chen CH: Primary effusion lymphoma involving both pleural and abdominal cavities in a patient with hepatitis B virus-related liver cirrhosis. J Formos Med Assoc; 2007 Jun;106(6):504-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an unusual form of non-Hodgkin's lymphoma, which is characterized by lymphomatous effusion in body cavities, but no associated mass lesions.
  • We describe a 54-year-old man with HIV-negative PEL, with a history of hepatitis B virus-related liver cirrhosis.
  • However, no durable remission was achieved.


67. Sirianni MC, Libi F, Campagna M, Rossi D, Capello D, Sciaranghella G, Carbone A, Simonelli C, Monini P, Gaidano G, Ensoli B: Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development. Br J Haematol; 2005 Jul;130(1):92-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development.
  • Primary effusion lymphomas (PELs) are invariably infected by human herpesvirus type 8 (HHV8) and often co-infected by Epstein-Barr virus (EBV).
  • We found that expression of major histocompatibility complex class I (MHC-I) surface molecules was significantly decreased in PEL cells when compared with HHV8 negative lymphomas, irrespective of EBV infection.
  • MHC-I downregulation rendered PEL cells sensitive to recognition and killing by natural killer (NK) cells.
  • Intriguingly, analysis of MHC-I non-restricted cytotoxicity in two PEL patients indicated a reduced NK cell activity when compared with healthy individuals.
  • These data suggest that PEL outgrowth may require an impaired NK cell function.
  • [MeSH-major] B-Lymphocytes / immunology. Herpesviridae Infections / immunology. Herpesvirus 8, Human. Histocompatibility Antigens Class I / analysis. Killer Cells, Natural / immunology. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / virology
  • [MeSH-minor] Biomarkers / analysis. Case-Control Studies. Cytotoxicity Tests, Immunologic. DNA, Viral / analysis. Down-Regulation. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / genetics. Humans. Serologic Tests

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2005 Oct;131(2):282
  • (PMID = 16044583.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


68. Towata T, Komizu Y, Suzu S, Ueoka R, Okada S: Highly selective fusion and accumulation of hybrid liposomes into primary effusion lymphoma cells along with induction of apoptosis. Biochem Biophys Res Commun; 2010 Mar 12;393(3):445-8
Hazardous Substances Data Bank. DODECYL ALCOHOL, ETHOXYLATED .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an aggressive neoplasm caused by human herpes virus-8 infection, and is generally resistant to chemotherapy.
  • Hybrid liposomes, composed of dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene (21) dodecyl ether (C12(EO)21) (HL-21), were rapidly accumulated in the membrane of PEL cells.
  • HL-21 also increased membrane fluidity of PEL cells, and induced caspase-3 activation along with cell death.
  • These results suggest that HL-21 should be an effective and attractive regent for PEL treatment.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20138834.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0AWH8BFG9A / polidocanol; 30IQX730WE / Polyethylene Glycols; U86ZGC74V5 / Dimyristoylphosphatidylcholine
  •  go-up   go-down


69. Ratel D, Ravanat JL, Charles MP, Platet N, Breuillaud L, Lunardi J, Berger F, Wion D: Undetectable levels of N6-methyl adenine in mouse DNA: Cloning and analysis of PRED28, a gene coding for a putative mammalian DNA adenine methyltransferase. FEBS Lett; 2006 May 29;580(13):3179-84
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undetectable levels of N6-methyl adenine in mouse DNA: Cloning and analysis of PRED28, a gene coding for a putative mammalian DNA adenine methyltransferase.
  • Three methylated bases, 5-methylcytosine, N4-methylcytosine and N6-methyladenine (m6A), can be found in DNA.
  • To reinvestigate the presence of m6A in mammalian DNA, we used a highly sensitive method capable of detecting one N6-methyldeoxyadenosine per million nucleosides.
  • Our results suggest that the total mouse genome contains, if any, less than 10(3) m6A.

  • HAL archives ouvertes. Full text from .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16684535.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 5142-22-3 / 1-methyladenine; EC 2.1.1.72 / PRED28 protein, mouse; EC 2.1.1.72 / Site-Specific DNA-Methyltransferase (Adenine-Specific); JAC85A2161 / Adenine
  •  go-up   go-down


70. Wen KW, Damania B: Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett; 2010 Mar 28;289(2):140-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV has been associated with the development of three neoplastic diseases: Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD).
  • In this review, we discuss the three KSHV-associated malignancies, KSHV genome, latent and lytic aspects of the viral lifecycle, putative viral oncogenes, as well as therapeutic regimens used for the treatment of KS, PEL, and MCD.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19651473.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA019014; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIAID NIH HHS / AI / T32 AI007001; United States / NIGMS NIH HHS / GM / T32-GM008719; United States / NIGMS NIH HHS / GM / T32 GM008719; United States / NIAID NIH HHS / AI / T32-AI007001; United States / NHLBI NIH HHS / HL / R01 HL083469; United States / NIDCR NIH HHS / DE / R01 DE018281; United States / NCI NIH HHS / CA / R01 CA096500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Ireland
  • [Number-of-references] 158
  • [Other-IDs] NLM/ NIHMS663850; NLM/ PMC4342847
  •  go-up   go-down


71. Snozek CL, Saenger AK, Greipp PR, Bryant SC, Kyle RA, Rajkumar SV, Katzmann JA: Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myeloma. Clin Chem; 2007 Jun;53(6):1099-103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two common albumin assays, bromcresol green (BCG) and agarose gel protein electrophoresis (PEL), frequently yield discordant results, creating confusion regarding which assay is superior for use in myeloma.
  • METHODS: We measured albumin by BCG on a Roche Modular system, by PEL with a Helena SPIFE SPE Vis agarose gel, and by immunonephelometry performed on a Dade Behring BNII nephelometer.
  • BCG and PEL were used to measure albumin in 5777 patient samples, and all 3 methods were used in an additional 252 samples.
  • RESULTS: For sera with zero/low monoclonal immunoglobulin protein (M)-spike (0 to <15 g/L), results for both BCG and PEL correlated well to nephelometry, although median PEL results were 8 g/L lower than corresponding BCG measurements.
  • Correlation between PEL and nephelometry or BCG diminished with increasing M-spike, with PEL eventually overestimating albumin compared with both other assays.
  • For 35% of myeloma patients, discrepancy between BCG and PEL had a potentially clinically significant effect on staging, but no difference in group survival was found.
  • CONCLUSIONS: Both BCG and PEL correlate well to nephelometry in sera with zero/low M-spikes.
  • In the presence of larger M-spikes, PEL correlates poorly to nephelometry or BCG, whereas BCG compares well with nephelometry regardless of M-spike.
  • [MeSH-major] Bromcresol Green. Multiple Myeloma / diagnosis. Serum Albumin / analysis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17463172.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62242
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indicators and Reagents; 0 / Paraproteins; 0 / Serum Albumin; 8YGN0Y942M / Bromcresol Green
  •  go-up   go-down


72. Cai SL, Lin JH, Wang CM, Lin L: [Improvement of the the thermostability of Penicillium expansum lipase by mutagenesis the random mutant ep8 at K55R]. Sheng Wu Gong Cheng Xue Bao; 2007 Jul;23(4):677-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to improve the thermostability of the Penicillium expansum Lipase (PEL), the lipase encoding genes was mutated by site-directed mutagenesis.
  • A recombinant vector pAO815-ep8-K55R which contain double mutant genes was constructed by overlap extension PCR using the cDNA of a random-mutant lipase ep8 (a single site mutant) as the template and two special primers were used to generate another mutation site K55R.
  • The recombinant vector was transformed into Pichia pastoris GS115 by electroporation and the recombinant mutant GS-pAO815-ep8- K55R can secret double-mutant lipase PEL-ep8-K55R-GS into the medium when it was induced by Methanol.
  • The yield of the double-mutant lipase is 508 u/mL, which is 81% that of the wild type lipase PEL-GS (627 u/mL) and 55% that of random-mutant PEL-ep8-GS (924 u/mL).
  • The specific activity of double-mutant lipase is 2309.1 u/mg, which is similar to random-mutant lipase PEL-ep8-GS and the wild type lipase PEL-GS.
  • The optimum temperature of the double-mutant lipase is same with the wild type lipase PEL-GS and random-mutant lipase PEL-ep8-GS.
  • While the Tm of the double-mutant lipase is 41.0 degrees C, 2.3 degrees C higher than the wild type lipase PEL-GS and 0.8% higher than the random-mutant lipase PEL-ep8-GS, indicating that the double-mutant lipase PEL-ep8-K55R-GS has higher thermostability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822043.001).
  • [ISSN] 1000-3061
  • [Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  • [ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mutant Proteins; 0 / Recombinant Proteins; EC 3.1.1.3 / Lipase
  •  go-up   go-down


73. Petre CE, Sin SH, Dittmer DP: Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol; 2007 Feb;81(4):1912-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) is associated with Kaposi's sarcoma (KS) as well as primary effusion lymphomas (PEL).
  • However, DNA-damaging drugs such as doxorubicin are clinically efficacious against PEL and KS, suggesting that p53 signaling remains intact despite the presence of KSHV.
  • To investigate the functionality of p53 in PEL, we examined the response of a large number of PEL cell lines to doxorubicin.
  • Two out of seven (29%) PEL cell lines harbored a mutant p53 allele (BCBL-1 and BCP-1) which led to doxorubicin resistance.
  • In contrast, all other PEL containing wild-type p53 showed DNA damage-induced cell cycle arrest, p53 phosphorylation, and p53 target gene activation.
  • Supporting this finding, chemical inhibition of p53 signaling in PEL led to doxorubicin resistance, and chemical activation of p53 by the Hdm2 antagonist Nutlin-3 led to unimpaired induction of p53 target genes as well as growth inhibition and apoptosis.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]
  • [Cites] Science. 1999 Sep 10;285(5434):1733-7 [10481009.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):431-44 [15558026.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Science. 1996 Nov 8;274(5289):948-53 [8875929.001]
  • [Cites] J Virol. 1997 Feb;71(2):1629-34 [8995690.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2606-10 [9366576.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] Oncogene. 2000 Mar 30;19(14):1834-42 [10777217.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] Oncogene. 1998 Mar;16(11):1429-41 [9525742.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1674-7 [9733514.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1677-9 [9733515.001]
  • [Cites] J Virol. 2005 Jul;79(13):8637-50 [15956606.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]
  • [Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3169-76 [16540668.001]
  • [Cites] Blood. 2006 May 15;107(10):4122-9 [16439677.001]
  • [Cites] Blood. 2006 May 15;107(10):4109-14 [16439685.001]
  • [Cites] Blood. 2006 Aug 1;108(3):993-1000 [16543464.001]
  • [Cites] J Virol. 2006 Sep;80(18):9017-30 [16940514.001]
  • [Cites] Arch Ophthalmol. 2006 Sep;124(9):1269-75 [16966622.001]
  • [Cites] J Biol Chem. 2006 Nov 3;281(44):33036-44 [16905769.001]
  • [Cites] J Virol. 2001 Jul;75(13):6193-8 [11390621.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] J Infect Dis. 2001 Jul 15;184(2):119-26 [11424007.001]
  • [Cites] Nature. 2001 Aug 30;412(6850):865-6 [11528457.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):383-93 [11839653.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13303-7 [14595027.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9030-40 [14663481.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):993-1000 [14707282.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] J Virol. 2004 May;78(10):5491-9 [15113928.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] J Virol. 2004 Sep;78(18):10074-85 [15331740.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Cancer Lett. 1993 May 14;69(3):151-60 [8513440.001]
  • (PMID = 17121789.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / T32 CA009156; United States / NCI NIH HHS / CA / CA009156; United States / NCI NIH HHS / CA / CA700580; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NCI NIH HHS / CA / CA109232-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Imidazoles; 0 / Piperazines; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 80168379AG / Doxorubicin; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC1797584
  •  go-up   go-down


74. Kopstein M: Potential uses of petrochemical products can result in significant benzene exposures: MSDSs must list benzene as an ingredient. J Occup Environ Hyg; 2006 Jan;3(1):1-8
Hazardous Substances Data Bank. BENZENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, according to the HCS, when the concentration of a carcinogen in a product is less than 0.1% (by weight) it may not be necessary to list it as an ingredient on the MSDS.
  • The standard stipulates that if potential uses of the product can result in exposures to the carcinogen that exceed the Occupational Safety and Health Administration (OSHA) permissible exposure limit or the ACGIH threshold limit value (TLV), then it must be listed.
  • Only rarely is benzene listed as an ingredient on MSDSs even though it often comprises more than 0.1% of petroleum solvents and, when its concentrations in petroleum-derived products are much less than 0.1%, inhalation exposures to benzene can be much higher that its OSHA PEL of one part per million (ppm) by volume (v/v) andACGIH TLV of/one-half ppm (v/v).
  • An exposure assessment methodology is presented that is applicable to employees whose conditions of exposure are similar to those in the published study.
  • These workers make up a similar exposure group.
  • [MeSH-major] Air Pollutants, Occupational / analysis. Benzene / analysis. Occupational Exposure. Safety Management. Solvents / analysis

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482972.001).
  • [ISSN] 1545-9624
  • [Journal-full-title] Journal of occupational and environmental hygiene
  • [ISO-abbreviation] J Occup Environ Hyg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Carcinogens; 0 / Petroleum; 0 / Solvents; J64922108F / Benzene
  •  go-up   go-down


75. Mazzella FM, Smith D, Horn P, Cotelingam JD, Rector JT, Shrit MA, Pesce A, Schumacher HR: Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients. Am J Hematol; 2006 Jul;81(7):484-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies of acute erythroleukemias have reaffirmed DiGuglielmo's syndrome (M6a, myeloblast-predominant) and disease (M6b, pronormoblast-predominant).
  • A 20-year retrospective study was performed to identify cases demonstrating >or=50% erythrocytic component and <30% calculated blasts (FAB exclusion criteria) without underlying cause (96 cases).
  • [MeSH-major] Erythroblasts. Leukemia, Erythroblastic, Acute / pathology. Models, Statistical. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Age Factors. Disease-Free Survival. Erythrocyte Count. Erythrocytes / pathology. Granulocyte Precursor Cells / pathology. Humans. Male. Middle Aged. Multivariate Analysis. Platelet Count. Predictive Value of Tests. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755568.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Sarek G, Järviluoma A, Ojala PM: KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood; 2006 Jan 15;107(2):725-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All PEL cells are latently infected with KSHV and express latent viral proteins such as the viral cyclin (v-cyclin), which has previously been implicated in down-regulation of cell-cycle inhibitor p27(KIP1) levels via phosphorylation on Thr187.
  • PEL cells retain high levels of p27(KIP1) but yet proliferate actively, which has left the biologic significance of this p27(KIP1) destabilization somewhat elusive.
  • We have recently demonstrated that v-cyclin and p27(KIP1) stably associate in PEL cells.
  • Here we demonstrate that v-cyclin together with its kinase partner CDK6 phosphorylates the associated p27(KIP1) in PEL cells, which represent a biologically relevant model system for KSHV pathobiology.
  • Interestingly, upon reactivation of KSHV lytic cycle, v-cyclin-CDK6 phosphorylated p27(KIP1) on Thr187, which resulted in down-regulation of p27(KIP1) protein levels.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160006.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclins; 0 / HHV8-Vcyc protein, Human herpesvirus 8; 0 / Viral Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 2ZD004190S / Threonine; 452VLY9402 / Serine; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  •  go-up   go-down


77. Li G, Rao L, Xue Y, Zhou C, Zhang Y, Ma Y: Cloning, expression, and characterization of a highly active alkaline pectate lyase from alkaliphilic Bacillus sp. N16-5. J Microbiol Biotechnol; 2010 Apr;20(4):670-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cloning, expression, and characterization of a highly active alkaline pectate lyase from alkaliphilic Bacillus sp. N16-5.
  • An alkaline pectate lyase, Bsp165PelA, was purified to homogeneity from the culture broth of alkaliphilic Bacillus sp. N16-5.
  • It was composed of a single polypeptide chain with a molecular of 42 kDa deduced from SDS-PAGE, and its isoelectric point was around pH 6.0.
  • The pectate lyase gene (pelA) contained an open reading frame (ORF) of 1089 bp, encoding a 36-amino acids signal peptide and a mature protein of 326 amino acids with a calculated molecular mass of 35.943 Da.
  • The deduced amino acid sequence from the pelA ORF exhibited significant homology to those of known pectate lyases in polysaccharide lyase family 1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467237.001).
  • [ISSN] 1017-7825
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GU088530
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / Pectins; 9046-38-2 / polygalacturonic acid; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


78. Shih TS, Kuo YC, Liang RH, Liou SH, Chang HY, Chou TC: Assessment of airborne and dermal exposure to 2-ethoxyethyl acetate in an occupational environment. Am J Ind Med; 2009 Aug;52(8):654-61
Hazardous Substances Data Bank. ETHYLENE GLYCOL MONOETHYL ETHER ACETATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of airborne and dermal exposure to 2-ethoxyethyl acetate in an occupational environment.
  • However, no actual occupational environmental studies or empirical dermal exposure measurements have been performed.
  • Environmental monitoring of EEAc exposure via respiratory and dermal routes was performed for five consecutive working days.
  • RESULTS: Airborne EEAc concentration was over the permissible exposure limit of 5 ppm in 90% of the participants.
  • The EEAc concentration correlated with skin exposure level (P < 0.001).
  • Wearing impermeable gloves during high-risk tasks (cleaning process) can reduce EEAc dermal exposure on the palms.
  • [MeSH-major] Air Pollution / adverse effects. Ethylene Glycols / toxicity. Occupational Diseases / chemically induced. Occupational Exposure / adverse effects. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Air Pollution.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19507184.001).
  • [ISSN] 1097-0274
  • [Journal-full-title] American journal of industrial medicine
  • [ISO-abbreviation] Am. J. Ind. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ethylene Glycols; DG1O0Z7390 / ethylene glycol monoethyl ether acetate
  •  go-up   go-down


79. Arias C, Walsh D, Harbell J, Wilson AC, Mohr I: Activation of host translational control pathways by a viral developmental switch. PLoS Pathog; 2009 Mar;5(3):e1000334
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To achieve a rapid gene expression transition, newly minted capped, polyadenylated viral mRNAs must engage and reprogram the cellular translational apparatus.
  • Using PEL-derived B-cells naturally infected with KSHV as a model, we define efficient reactivation conditions and demonstrate that reactivation substantially changes the protein synthesis profile.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1926-30 [3031658.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1871-80 [10022874.001]
  • [Cites] Curr Opin Struct Biol. 2005 Feb;15(1):99-106 [15718140.001]
  • [Cites] J Virol. 2005 May;79(9):5499-506 [15827164.001]
  • [Cites] Curr Opin Cell Biol. 2005 Jun;17(3):251-6 [15901493.001]
  • [Cites] J Virol. 2005 Jul;79(13):8057-64 [15956551.001]
  • [Cites] Annu Rev Genet. 2005;39:409-29 [16285866.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] Genes Dev. 2006 Feb 15;20(4):461-72 [16481474.001]
  • [Cites] J Gen Virol. 2006 Apr;87(Pt 4):795-802 [16528027.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1139-44 [16603514.001]
  • [Cites] Adv Virus Res. 2006;66:337-94 [16877064.001]
  • [Cites] Virology. 2006 Aug 15;352(1):100-9 [16716377.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:157-83 [17089797.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3366-71 [17360652.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):452-7 [17762570.001]
  • [Cites] PLoS One. 2007;2(10):e1067 [17957251.001]
  • [Cites] Front Biosci. 2008;13:2928-38 [17981766.001]
  • [Cites] J Virol. 2007 Dec;81(23):12973-8 [17881455.001]
  • [Cites] Mol Cell. 2007 Nov 9;28(3):501-12 [17996713.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3232-7 [18055695.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(8):2648-58 [18250159.001]
  • [Cites] Front Biosci. 2008;13:5241-56 [18508584.001]
  • [Cites] J Gen Virol. 1999 Dec;80 ( Pt 12):3207-15 [10567653.001]
  • [Cites] J Virol. 2000 Apr;74(8):3586-97 [10729134.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] J Virol. 2000 Dec;74(23):10920-9 [11069986.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] Virology. 2001 Aug 15;287(1):62-70 [11504542.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] Nat Neurosci. 2003 Mar;6(3):219-20 [12592407.001]
  • [Cites] J Virol. 2003 Apr;77(7):4205-20 [12634378.001]
  • [Cites] J Virol. 2003 Jul;77(14):8147-52 [12829853.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):713-23 [15023341.001]
  • [Cites] Genes Dev. 2004 Mar 15;18(6):660-72 [15075293.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6539-49 [15254222.001]
  • [Cites] J Virol. 1976 Dec;20(3):583-8 [186635.001]
  • [Cites] J Virol. 1989 May;63(5):1897-906 [2539493.001]
  • [Cites] Eur J Biochem. 1993 Nov 15;218(1):39-48 [8243475.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11883-8 [8876232.001]
  • [Cites] J Virol. 1997 Feb;71(2):1207-12 [8995643.001]
  • [Cites] EMBO J. 1997 Apr 15;16(8):1909-20 [9155017.001]
  • [Cites] EMBO J. 1997 Apr 15;16(8):1921-33 [9155018.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3269-73 [9531283.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):9373-7 [9545260.001]
  • [Cites] EMBO J. 1999 Jan 4;18(1):270-9 [9878069.001]
  • (PMID = 19300492.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM056927; United States / NIGMS NIH HHS / GM / GM61139; United States / NIGMS NIH HHS / GM / R01 GM061139; United States / NCRR NIH HHS / RR / S10 RR017970; United States / NIAID NIH HHS / AI / AI073898; United States / NIGMS NIH HHS / GM / GM056927; United States / NIAID NIH HHS / AI / R01 AI073898; United States / NIAID NIH HHS / AI / P30 AI027742
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / EIF4ENIF1 protein, human; 0 / Immediate-Early Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nucleocytoplasmic Transport Proteins; 0 / Phosphoproteins; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; EC 2.7.1.- / MKNK1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2652079
  •  go-up   go-down


80. Blake CL, Dotson GS, Harbison RD: Evaluation of asbestos exposure within the automotive repair industry: a study involving removal of asbestos-containing body sealants and drive clutch replacement. Regul Toxicol Pharmacol; 2008 Dec;52(3):324-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of asbestos exposure within the automotive repair industry: a study involving removal of asbestos-containing body sealants and drive clutch replacement.
  • The first involved removal of asbestos-containing seam sealant, and the second involved servicing of a drive clutch.
  • Many other air samples contained asbestos at or below the analytical limit of detection (LOD).
  • Asbestos fibers were only detected in air samples collected during the installation of a replacement clutch.
  • This value is approximately 100 times lower than Occupational Safety and Health Administration's (OSHA) permissible exposure limit (PEL) of 0.1f/cc.
  • The airborne asbestos concentrations observed during the servicing of vintage vehicles with asbestos-containing seam sealant and clutches are comparable to levels reported for repair work involving brake components and gaskets.
  • [MeSH-major] Air Pollutants, Occupational / analysis. Asbestos, Serpentine / analysis. Environmental Monitoring. Motor Vehicles. Occupational Exposure / analysis

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18809452.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Asbestos, Serpentine
  •  go-up   go-down


81. Cichon T, Smolarczyk R, Sochanik A, Szala S: Plasmid DNA-induced cytokines together with cyclophosphamide decrease size and number of melanoma lung metastases. Anticancer Res; 2006 May-Jun;26(3A):2033-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To destroy small metastases remaining after CTX treatment, pro-inflammatory cytokines were induced by systemically administering plasmid DNA-PEl polyplexes.
  • Our data indicated, for the first time, that combining cyclophosphamide delivery and local induction of pro-inflammatory cytokines in the lungs with plasmid DNA resulted in reduction in the size of malignant melanoma metastases and their number in mouse lungs.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827141.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cytokines; 8N3DW7272P / Cyclophosphamide; 9002-98-6 / Polyethyleneimine; 9007-49-2 / DNA
  •  go-up   go-down


82. Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS: Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci U S A; 2010 Jul 20;107(29):13069-74
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an aggressive B-cell lymphoma most commonly diagnosed in HIV-positive patients and universally associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • Chemotherapy treatment of PEL yields only short-term remissions in the vast majority of patients, but efforts to develop superior therapeutic approaches have been impeded by lack of animal models that accurately mimic human disease.
  • To address this issue, we developed a direct xenograft model, UM-PEL-1, by transferring freshly isolated human PEL cells into the peritoneal cavities of NOD/SCID mice without in vitro cell growth to avoid the changes in KSHV gene expression evident in cultured cells.
  • We used this model to show that bortezomib induces PEL remission and extends overall survival of mice bearing lymphomatous effusions.
  • The proapoptotic effects of bortezomib are not mediated by inhibition of the prosurvival NF-kappaB pathway or by induction of a terminal unfolded protein response.
  • Transcriptome analysis by genomic arrays revealed that bortezomib down-regulated cell-cycle progression, DNA replication, and Myc-target genes.
  • Our findings show that this direct xenograft model can be used for testing novel PEL therapeutic strategies and also can provide a rational basis for evaluation of bortezomib in clinical trials.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):165-74 [10343068.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Leuk Res. 2005 May;29(5):545-55 [15755507.001]
  • [Cites] Mol Cancer Ther. 2005 Mar;4(3):443-9 [15767553.001]
  • [Cites] Methods. 2005 Apr;35(4):373-81 [15804610.001]
  • [Cites] Blood. 2005 May 15;105(10):4028-34 [15687238.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] Antivir Ther. 2005;10(6):745-51 [16218174.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4907-16 [16507771.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17834-9 [17093053.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):245-58 [17349582.001]
  • [Cites] Oncologist. 2007 May;12(5):569-76 [17522245.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4979-86 [17310999.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1099-105 [17895889.001]
  • [Cites] J Biol Chem. 2009 Apr 24;284(17):11121-33 [19261616.001]
  • [Cites] Br J Haematol. 2009 Nov;147(3):308-18 [19694722.001]
  • [Cites] Blood. 2010 Jan 21;115(3):570-80 [19965678.001]
  • [Cites] Blood. 2010 Jun 3;115(22):4455-63 [20299510.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1797-803 [10688840.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):729-36 [10793109.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] J Virol. 2001 Apr;75(7):3250-8 [11238851.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2641-8 [11289142.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3071-6 [11306489.001]
  • [Cites] Oncogene. 2001 Oct 25;20(48):7029-40 [11704827.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1099-108 [11106749.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9007-21 [14663479.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):514-23 [14724579.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):114-9 [16311516.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1699-704 [15343345.001]
  • [Cites] J Biol Chem. 1988 Apr 25;263(12):5526-33 [3356695.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):5015-25 [8756660.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • (PMID = 20615981.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE22594
  • [Grant] United States / PHS HHS / / 5P30A1073961; United States / NCI NIH HHS / CA / R01 CA136387; United States / NCI NIH HHS / CA / CA75918; United States / NCI NIH HHS / CA / CA136387; United States / NCI NIH HHS / CA / CA122105; United States / NIAID NIH HHS / AI / P30 AI073961; United States / NCI NIH HHS / CA / U54 CA149145; United States / NCI NIH HHS / CA / R01 CA075918; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105; United States / NCI NIH HHS / CA / CA109335; United States / NCI NIH HHS / CA / 1U54CA149145-01
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / E2F3 Transcription Factor; 0 / E2f3 protein, mouse; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-myc; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Other-IDs] NLM/ PMC2919898
  •  go-up   go-down


83. Ahmad A, Groshong JS, Matta H, Schamus S, Punj V, Robinson LJ, Gill PS, Chaudhary PM: Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. Cancer Biol Ther; 2010 Nov 15;10(10):1033-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an aggressive form of lymphoma that is associated with infection by Kaposi's sarcoma-associated herpesvirus (KSHV).
  • One of the KSHV genes expressed in PEL cells is K13, a potent activator of the NF-κB pathway.
  • A possible candidate that could cooperate with K13 in the development of PEL is c-Myc, whose expression is frequently dysregulated in PEL cells.
  • To study the cooperative interaction between K13 and c-Myc in the pathogenesis of PEL, we crossed the K13 transgenic mice to iMyc(Eμ) transgenic mice that overexpress Myc.
  • Lymphomas in the K13/iMyc(Eμ) mice also lacked the expression of B- and T-cell markers, thus resembling the immunophenotype of PEL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 May 4;25(19):2717-26 [16418726.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12885-90 [16120683.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Virol. 2006 Jul;80(14):7179-85 [16809323.001]
  • [Cites] J Gen Virol. 2007 Jan;88(Pt 1):46-50 [17170435.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2700-7 [17119127.001]
  • [Cites] Oncologist. 2007 May;12(5):569-76 [17522245.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4979-86 [17310999.001]
  • [Cites] J Virol. 2007 Oct;81(19):10451-9 [17634226.001]
  • [Cites] PLoS One. 2007;2(10):e1067 [17957251.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):31944-53 [17728244.001]
  • [Cites] Cancer Biol Ther. 2008 Apr;7(4):603-8 [18223318.001]
  • [Cites] Br J Haematol. 2008 Oct;143(1):3-15 [18573107.001]
  • [Cites] J Virol. 2009 Jan;83(2):598-611 [18987137.001]
  • [Cites] Nat Cell Biol. 2009 Nov;11(11):1355-62 [19838173.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1725-33 [10528022.001]
  • [Cites] Semin Immunol. 2000 Feb;12(1):85-98 [10723801.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1956-61 [12406869.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Leukemia. 2004 Jan;18(1):11-7 [14574329.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52437-45 [14563855.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] J Clin Invest. 2004 Jun;113(12):1763-73 [15199411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404 [15190178.001]
  • [Cites] Front Biosci. 1998 Feb 15;3:d250-68 [9468463.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):203-8 [15380510.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):331-3 [2250704.001]
  • [Cites] Oncogene. 1993 Oct;8(10):2741-8 [8397370.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):56-61 [8220424.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):269-75 [7846125.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Behring Inst Mitt. 1996 Oct;(97):101-17 [8950469.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):517-21 [9087414.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Blood. 1998 Jul 1;92(1):234-40 [9639522.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1317-22 [9721090.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2967-87 [10378693.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5738-46 [10523854.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1306-15 [15735016.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):469-73 [16093798.001]
  • [Cites] Curr Mol Med. 2006 May;6(3):291-308 [16712476.001]
  • (PMID = 20818173.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085177; United States / NHLBI NIH HHS / HL / R21 HL085189; United States / NCI NIH HHS / CA / CA85177; United States / NHLBI NIH HHS / HL / HL085189
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Viral Proteins; 0 / viral FLIP protein, Human herpesvirus 8
  • [Other-IDs] NLM/ PMC3047095
  •  go-up   go-down


84. Stewart CJ, Brennan BA, Crook ML, Russell P: Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours. Histopathology; 2007 Sep;51(3):313-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours.
  • AIMS: To determine whether elastin stains aid in classifying peritoneal implants associated with ovarian serous borderline tumours (SBT).
  • Elastin stains were performed using histochemical and immunohistochemical methods to demonstrate the peritoneal elastic lamina (PEL), and evaluated with regard to assessment of the subtype of implant.
  • The elastin stains demonstrated the PEL in most anatomical sites other than the omentum and the bladder and were considered helpful in 44/80 (55%) cases.
  • The staining was non-contributory in most of the remaining biopsies, because the PEL was not identified.
  • CONCLUSIONS: Demonstration of the PEL using elastin stains can be useful in the subclassification of implants associated with ovarian SBT and is of most value in confirming the superficial distribution of non-invasive lesions.
  • However, evaluation is limited by the absence of a defined elastic layer in a proportion of biopsy specimens, possibly reflecting their superficial location, as well as absence of a distinct PEL in sites such as the omentum.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727474.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9007-58-3 / Elastin
  •  go-up   go-down


85. Hansen AM, Gonzalez-Marquez LC: Scenarios of metal concentrations in the Arcediano Dam (State of Jalisco, Mexico). J Environ Sci Health A Tox Hazard Subst Environ Eng; 2010;45(1):99-106
Hazardous Substances Data Bank. HEMATITE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For sediment samples in the river, chrome, copper and zinc exceeded the Canadian Interim Sediment Quality Guidelines (ISQG), whereas manganese and nickel exceeded the probable effect level (PEL).
  • Other metals were below these limits.

  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20390848.001).
  • [ISSN] 1532-4117
  • [Journal-full-title] Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering
  • [ISO-abbreviation] J Environ Sci Health A Tox Hazard Subst Environ Eng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Metals; 0 / Water Pollutants, Chemical; 1K09F3G675 / ferric oxide
  •  go-up   go-down


86. Menon KN, Ikeda T, Fujimoto I, Narimatsu H, Nakakita S, Hase S, Ikenaka K: Changes in N-linked sugar chain patterns induced by moderate-to-high expression of the galactosyltransferase I gene in a brain-derived cell line, CG4. J Neurosci Res; 2005 Apr 1;80(1):29-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in N-linked sugar chain patterns induced by moderate-to-high expression of the galactosyltransferase I gene in a brain-derived cell line, CG4.
  • Oligosaccharides with biantennae and bisecting N-acetyl glucosamine (GlcNAc) residues attached to the mannose in the beta1-4 trimannosyl core (BA2) are enriched in the brain and considered brain-type sugar chains.
  • Increased GalTase expression in different glial- and neuronal-derived cell lines was accompanied by decreased or undetectable levels of BA2, depending on the level of GalTase expression.
  • Forceful expression of GalTase I in CG4 cells expressing high levels of BA2 and low GalTase activity significantly reduced BA2 levels.
  • The increased levels of A1(6)G1Fo indicate a diversion or abrogation of the N-linked sugar chain biosynthetic pathway from normal.
  • The accumulation of A1(6)G1Fo and increased A2G2Fo(6)F levels were accompanied by decreased levels of the high mannose-type sugar chains, M5A, M6B, M8A, and M9A.
  • [MeSH-minor] Acetylglucosamine / chemistry. Acetylglucosamine / metabolism. Animals. Cell Line. Chromatography, High Pressure Liquid. Gene Expression. Humans. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15723386.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligosaccharides; EC 2.4.1.- / Galactosyltransferases; EC 2.4.1.133 / xylosylprotein 4-beta-galactosyltransferase; V956696549 / Acetylglucosamine
  •  go-up   go-down


87. Kitagawa J, Hara T, Tsurumi H, Oyama M, Moriwaki H: Pure erythroid leukemia with hemophagocytosis. Intern Med; 2009;48(18):1695-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure erythroid leukemia with hemophagocytosis.
  • Biochemistry showed increased ferritin levels.
  • Pure erythroid leukemia with hemophagocytic syndrome (HPS) was diagnosed.
  • Complete remission was attained, and HPS also improved.
  • However, leukemia relapsed during chemotherapy and the patient died.
  • This is the first report of pure erythroid leukemia complicated with HPS.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / complications. Lymphohistiocytosis, Hemophagocytic / etiology

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755777.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; X4W7ZR7023 / Methylprednisolone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


88. Calabrò ML, Gasperini P, Di Gangi IM, Indraccolo S, Barbierato M, Amadori A, Chieco-Bianchi L: Antineoplastic activity of lentiviral vectors expressing interferon-alpha in a preclinical model of primary effusion lymphoma. Blood; 2009 May 7;113(19):4525-33
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The peculiar site of development of primary effusion lymphoma (PEL) highlights a specific role of body cavities in the pathogenesis of this neoplasia.
  • We used a xenograft murine model of PEL to characterize the contribution of the host microenvironment to PEL growth.
  • The activity of a murine (ie, host-specific) interferon-alpha(1) (IFN-alpha(1))-expressing lentiviral vector (mIFN-alpha(1)-LV) was compared with that of a human (h) IFN-alpha(2)b-LV.
  • LVs efficiently delivered the transgene to PEL cells and conferred long-term transgene expression in vitro and in vivo.
  • Treatment of PEL-injected severe combined immunodeficiency mice with hIFN-alpha(2)b-LV significantly prolonged mice survival and reduced ascites development.
  • As mIFN-alpha(1) retained species-restricted activity in vitro, it probably acted in vivo on the intracavitary murine milieu. mIFN-alpha(1)-treated murine mesothelial cells were found to express tumor necrosis factor-related apoptosis-inducing ligand and to significantly trigger apoptosis of cocultured PEL cells in a tumor necrosis factor-related apoptosis-inducing ligand-dependent manner.
  • These data suggest that the interaction between lymphomatous and mesothelial cells lining the body cavities may play a key role in PEL growth control and also indicate that the specific targeting of microenvironment may impair PEL development.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19196659.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


89. Jose M, Sivapirakasam SP, Surianarayanan M: Analysis of aerosol emission and hazard evaluation of electrical discharge machining (EDM) process. Ind Health; 2010;48(4):478-86
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The safety and environmental aspects of a manufacturing process are important due to increased environmental regulations and life quality.
  • The pattern of aerosol emissions from this process with varying process parameters such as peak current, pulse duration, dielectric flushing pressure and the level of dielectric was evaluated.
  • The analysis of aerosol exposure showed that the concentration of aerosol was increased with increase in the peak current, pulse duration and dielectric level and was decreased with increase in the flushing pressure.
  • It was also found that at higher values of peak current (7A) and pulse duration (520 micros), the concentration of aerosols at breathing zone of the operator was above the permissible exposure limit value for respirable particulates (5 mg/m(3)).
  • [MeSH-major] Aerosols / analysis. Air Pollutants, Occupational / analysis. Manufactured Materials. Occupational Exposure / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20720340.001).
  • [ISSN] 1880-8026
  • [Journal-full-title] Industrial health
  • [ISO-abbreviation] Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aerosols; 0 / Air Pollutants, Occupational
  •  go-up   go-down


90. Carbone A, Gloghini A: KSHV/HHV8-associated lymphomas. Br J Haematol; 2008 Jan;140(1):13-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review looks at the current state of knowledge on primary effusion lymphoma (PEL) and other Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus 8 (HHV8)-associated lymphomas.
  • In 1995, KSHV DNA sequences were identified within a distinct subgroup of acquired immunodeficiency syndrome-related non-Hodgkin lymphomas localized in body cavities and presenting as pleural, peritoneal and pericardial lymphomatous effusions.
  • KSHV/HHV8 infection is also in multicentric Castleman disease-associated plasmablastic lymphoma.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991301.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


91. Xie X, He Y, Tian F, Seah HS, Gu X, Qin H: An effective illustrative visualization framework based on photic extremum lines (PELs). IEEE Trans Vis Comput Graph; 2007 Nov-Dec;13(6):1328-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We compare PELs with the existing approaches and demonstrate that PEL is a flexible and effective tool to illustrate 3D surface and volume for visual computing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968081.001).
  • [ISSN] 1077-2626
  • [Journal-full-title] IEEE transactions on visualization and computer graphics
  • [ISO-abbreviation] IEEE Trans Vis Comput Graph
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Liu Y, Yang CH, Li J: Influence of extracellular polymeric substances on Pseudomonas aeruginosa transport and deposition profiles in porous media. Environ Sci Technol; 2007 Jan 1;41(1):198-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of EPS on nonmucoid strain PA01 and mucoid strain PD0300 significantly increased bacterial adhesion over the EPS deficient PA01 psl pel mutant strain despite their similar surface charge as indicated by the zeta potential measurements.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17265948.001).
  • [ISSN] 0013-936X
  • [Journal-full-title] Environmental science & technology
  • [ISO-abbreviation] Environ. Sci. Technol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbohydrates; 0 / Uronic Acids
  •  go-up   go-down


93. Laouar A, Manocha M, Wan M, Yagita H, van Lier RA, Manjunath N: Cutting Edge: Distinct NK receptor profiles are imprinted on CD8 T cells in the mucosa and periphery during the same antigen challenge: role of tissue-specific factors. J Immunol; 2007 Jan 15;178(2):652-6
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NK cell receptors (NKRs) modulate T lymphocyte responses by modifying the Ag activation threshold.
  • After a viral, bacterial, and tumor challenge, most CD8 peritoneal exudate lymphocytes expressed NKG2A but not 2B4.
  • In contrast, most CD8 intraepithelial lymphocytes exhibited 2B4 but not NKG2A.
  • [MeSH-major] Antigens / immunology. CD8-Positive T-Lymphocytes / immunology. Immunity, Mucosal. Killer Cells, Natural / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202324.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 46566
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, CD70; 0 / Klrc1 protein, mouse; 0 / NK Cell Lectin-Like Receptor Subfamily C; 0 / Receptors, Immunologic; 0 / Receptors, Natural Killer Cell; 5688UTC01R / Tretinoin
  •  go-up   go-down


94. Asplin KE, Patterson-Kane JC, Sillence MN, Pollitt CC, Mc Gowan CM: Histopathology of insulin-induced laminitis in ponies. Equine Vet J; 2010 Nov;42(8):700-6
MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To describe the histological appearance and quantify morphological changes in primary and secondary epidermal lamellae (PEL and SEL) of laminitis lesions from ponies with insulin-induced laminitis.
  • Measurements of lamellar length (PEL and SEL) were made in mid-dorsal sections of the right forefeet by 2 blinded observers.
  • Within ponies, SEL lesions were more severe along the axial region of PEL.
  • SEL were significantly elongated in laminitic hooves relative to controls, with the greatest elongation in those attached to abaxial and middle regions of PEL.
  • CONCLUSIONS: Laminitis induced by prolonged infusion of insulin lacked widespread basement membrane disintegration, and increases in epidermal cellular proliferation at axial aspects were marked for this acute stage of disease.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 EVJ Ltd.
  • (PMID = 21039799.001).
  • [ISSN] 0425-1644
  • [Journal-full-title] Equine veterinary journal
  • [ISO-abbreviation] Equine Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin; 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


95. Gluzman DF, Nadgornaya VA, Sklyarenko LM, Zavelevych MP, Koval SV, Poludnenko LY, Ivanovskaya TS: Study of morphocytochemical and immunophenotypic features of acute leukemia stem cells. Exp Oncol; 2008 Jun;30(2):102-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of morphocytochemical and immunophenotypic features of acute leukemia stem cells.
  • The results of our studies suggest that the standard panel for classification of acute leukemias should be supplemented with several new markers allowing us to identify more precisely the different forms of the leukemias being of the closely related origin, for example AML M6b and AML M7.
  • The common bipotent LSC in AML M7 of low grade and AML M6b may exist analogous to precursor cell common for megakaryocytopoiesis and erythropoiesis.
  • We have also found the similarity between blast cells in pro-B-ALL [t (4;11), 11q23] and AML M5a [t (9;11), 11q23].
  • Such similarity of immunophenotype and cytogenetic abnormalities in blast cells in pro-B-ALL and AML M5a may be considered as hint explaining the cases of AML M5a as a recurrence of leukemia in children with originally diagnosed pro-B-ALL.
  • [MeSH-major] Immunophenotyping / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Child. Hematopoietic Stem Cells / cytology. Humans. Leukemia / pathology. Megakaryocytes / metabolism. Mice. Mice, SCID. Neoplastic Stem Cells / cytology. Stem Cells / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18566571.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ukraine
  • [Number-of-references] 25
  •  go-up   go-down


96. Muromoto R, Okabe K, Fujimuro M, Sugiyama K, Yokosawa H, Seya T, Matsuda T: Physical and functional interactions between STAT3 and Kaposi's sarcoma-associated herpesvirus-encoded LANA. FEBS Lett; 2006 Jan 9;580(1):93-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded latency-associated nuclear antigen (LANA) is known to modulate viral and cellular gene expression.
  • Coimmunoprecipitation studies documented a physical interaction between LANA and STAT3 in transiently transfected 293T cells as well as the KSHV-infected primary effusion lymphoma (PEL) cell line.
  • Furthermore, small-interfering RNA-mediated reduction of LANA expression decreased the STAT3-dependent transcription in KSHV-positive PEL cells, whereas overexpression of LANA enhanced STAT3 activity in KSHV-negative B lymphoma cells.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364321.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / latency-associated nuclear antigen
  •  go-up   go-down


97. Miller A, Drake PL, Hintz P, Habjan M: Characterizing exposures to airborne metals and nanoparticle emissions in a refinery. Ann Occup Hyg; 2010 Jul;54(5):504-13
Hazardous Substances Data Bank. SILVER, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of filter samples indicated that all of the workers were exposed to levels of silver above the Occupational Safety and Health Administration permissible exposure limit of 0.01 mg m(-3) even though the localized ventilation was functioning.
  • Results of the survey were used to deduce appropriate strategies for mitigation of worker exposure to airborne metals.
  • [MeSH-major] Air Pollutants, Occupational / analysis. Metals / analysis. Nanoparticles / analysis. Occupational Exposure / analysis
  • [MeSH-minor] Aerosols / analysis. Aerosols / chemistry. Air Pollution, Indoor / analysis. Air Pollution, Indoor / statistics & numerical data. Dust / analysis. Environmental Monitoring. Filtration / instrumentation. Humans. Inhalation Exposure / analysis. Inhalation Exposure / standards. Inhalation Exposure / statistics & numerical data. Mass Spectrometry. Metallurgy. Microscopy, Electron, Transmission. Particle Size. Silver / analysis. Spectrometry, X-Ray Emission. Threshold Limit Values. Workplace / standards

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403942.001).
  • [ISSN] 1475-3162
  • [Journal-full-title] The Annals of occupational hygiene
  • [ISO-abbreviation] Ann Occup Hyg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aerosols; 0 / Air Pollutants, Occupational; 0 / Dust; 0 / Metals; 3M4G523W1G / Silver
  •  go-up   go-down


98. Malkin R, Lentz TJ, Topmiller J, Hudock SD, Niemeier RW: The characterization of airborne occupational safety and health hazards in selected small businesses; manufacturing wood pallets. Ind Health; 2006 Jan;44(1):58-63
Hazardous Substances Data Bank. Carbon monoxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carbon monoxide (CO) levels, noise levels, and total particulate were measured, ergonomic observations made, and occupational safety practices analyzed at each of the four facilities where measurements were taken.
  • 1) CO levels in three plants, for the time periods measured, were less than the OSHA permissible exposure limit (PEL) of 50 parts per million (ppm) for an 8-h TWA.
  • [MeSH-major] Air Pollutants / analysis. Hazardous Substances / analysis. Industry. Occupational Exposure. Occupational Health

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16610535.001).
  • [ISSN] 0019-8366
  • [Journal-full-title] Industrial health
  • [ISO-abbreviation] Ind Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Hazardous Substances; 7U1EE4V452 / Carbon Monoxide
  •  go-up   go-down


99. Lambe JS, Oble DA, Nandula SV, Sevilla DW, Colovai AI, Mansukhani M, Chari A, Murty VV, Alobeid B, Bhagat G: KHSV(-) EBV(-) post-transplant effusion lymphoma with plasmablastic features: variant of primary effusion lymphoma? Hematol Oncol; 2009 Dec;27(4):203-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare type of B-cell non-Hodgkin lymphoma (NHL), which predominantly occurs in HIV-infected individuals, and is pathogenetically linked with Kaposi sarcoma (KS)-associated herpes virus/human herpes virus-8 (KSHV/HHV-8) infection with or without evidence of Epstein-Barr virus (EBV) co-infection.
  • Rare cases of KSHV(-) EBV(+) post-transplant effusion lymphomas resembling PEL have also been described, as have KSHV(-) EBV(-) effusion lymphomas, the latter including those arising in individuals with chronic liver disease.
  • We report a unique KSHV(-) EBV(-) post-transplant effusion lymphoma associated with serum paraproteins, occurring in an HIV(-) individual, which had cytologic features and phenotype similar to PEL, and displayed a complex karyotype including isochromosome 12p and translocation t(8;22), resulting in rearrangement of c-MYC.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19337983.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Venizelos I, Tamiolakis D, Lambropoulou M, Nikolaidou S, Bolioti S, Papadopoulos H, Papadopoulos N: An unusual case of posttransplant peritoneal primary effusion lymphoma with T-cell phenotype in a HIV-negative female, not associated with HHV-8. Pathol Oncol Res; 2005;11(3):178-81
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of posttransplant peritoneal primary effusion lymphoma with T-cell phenotype in a HIV-negative female, not associated with HHV-8.
  • Primary effusion lymphoma (PEL) is a recently individualized form of non-Hodgkin's lymphoma (WHO classification) that mainly develops in HIV infected males, more frequently in homosexuals and advanced stages of the disease (total CD4+ lymphocyte count below 100-200/microL).
  • From a pathogenetic point of view, PEL has been related to Kaposi's sarcoma associated herpes virus (also named human herpesvirus 8, HHV-8), an etiological factor of Kaposi's sarcoma.
  • The relative infrequency of this disease, the absence of wide casuistics allowing a better characterization, and its unfavorable outcome support the need of a deeper knowledge.
  • We present here the clinical-biological findings of a patient, HIV seronegative, who was diagnosed with peritoneal PEL of T-cell origin, and not HHV-8-associated, five years after renal transplantation.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Respir J. 1999 Nov;14(5):1231-4 [10596717.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):595-601 [12002764.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413-7 [2052620.001]
  • [Cites] Leukemia. 2000 Feb;14(2):271-7 [10673744.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]
  • [Cites] Eur J Haematol. 2003 Jul;71(1):62-7 [12801300.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S56-67 [9894470.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):809-16 [14526684.001]
  • [Cites] Leuk Lymphoma. 2000 Feb;36(5-6):447-56 [10784388.001]
  • (PMID = 16195773.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30
  •  go-up   go-down






Advertisement